EP0032058A1 - Thiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same - Google Patents
Thiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same Download PDFInfo
- Publication number
- EP0032058A1 EP0032058A1 EP80304740A EP80304740A EP0032058A1 EP 0032058 A1 EP0032058 A1 EP 0032058A1 EP 80304740 A EP80304740 A EP 80304740A EP 80304740 A EP80304740 A EP 80304740A EP 0032058 A1 EP0032058 A1 EP 0032058A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- salt
- mixture
- thiazole
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
Definitions
- the present invention relates to novel thiazole derivatives and pharmaceutically acceptable salts thereof. More particularly, it relates to novel thiazole derivatives and pharmaceutically acceptable salts thereof which have antiallergic activities, to processes for the preparation thereof, to pharmaceutical composition comprising the same, and to a method of using the same therapeutically in the treatment of allergic symptoms in human being and animals.
- Another object of the present invention is to provide processes for the preparation of thiazole derivatives and pharmaceutically acceptable salts thereof.
- a further object of the present invention is to provide pharmaceutical composition comprising, as an active ingredient, said thiazole derivative or its pharmaceutically acceptable salt.
- Still further object of the present invention is to provide a method of using said thiazole derivative or its pharmaceutically acceptable salt in the treatment of allergic symptoms in human being and animals.
- the object thiazole derivatives of the present invention are novel and can be represented by the following formula (I) :
- Suitable "lower alkyl” may include straight or branched one such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl and the like, in which the preferred one is C l -C 4 alkyl.
- acyl may include an aliphatic acyl, an aromatic acyl, a heterocyclic acyl and an aliphatic acyl substituted with aromatic or heterocyclic group(s).
- the aliphatic acyl may include saturated or unsaturated, acyclic or cyclic ones, such as lower alkanoyl (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, etc.), lower alkanesulfonyl (e.g. methanesulfonyl, ethanesulfonyl, propanesulfonyl, butanesulfonyl, etc.), lower alkoxycarbonyl (e.g.
- lower alkanoyl e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, etc.
- lower alkanesulfonyl e.g. methanesulfonyl, ethanesul
- N-lower alkylcarbamoyl e.g. N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, etc.
- lower alkoxalyl e.g. methoxalyl, ethoxalyl, propoxalyl, etc.
- lower alkenoyl e.g. acryloyl, methacryloyl, crotonoyl, etc.
- C3-C7 ⁇ -cycloalkanecarbonyl e.g. cyclohexanecarbonyl, etc.
- the aromatic acyl may include aroyl (e.g. benzoyl, toluoyl, xyloyl, etc.), arenesulfonyl (e.g. benzenesulfonyl, tosyl, etc.), and the like.
- aroyl e.g. benzoyl, toluoyl, xyloyl, etc.
- arenesulfonyl e.g. benzenesulfonyl, tosyl, etc.
- the heterocyclic acyl may include heterocycle- carbonyl (e.g. furoyl, thenoyl, nicotinoyl, isonicotinoyl, thiazolylcarbonyl, thiadiazolylcarbonyl, tetrazolylcarbonyl, etc.), and the like.
- heterocycle- carbonyl e.g. furoyl, thenoyl, nicotinoyl, isonicotinoyl, thiazolylcarbonyl, thiadiazolylcarbonyl, tetrazolylcarbonyl, etc.
- the aliphatic acyl substituted with aromatic group(s) may include phenyl(lower)alkanoyl (e.g. phenylacetyl, phenylpropionyl, phenylhexanoyl, etc.), phenyl(lower)-alkoxycarbonyl (e.g. benzyloxycarbonyl, phenethyloxycarbonyl, etc.), phenoxy(lower)alkanoyl (e.g. phenoxyacetyl, phenoxypropionyl, etc.), and the like.
- phenyl(lower)alkanoyl e.g. phenylacetyl, phenylpropionyl, phenylhexanoyl, etc.
- phenyl(lower)-alkoxycarbonyl e.g. benzyloxycarbonyl, phenethyloxycarbonyl, etc.
- the aliphatic acyl substituted with heterocyclic group(s) may include thienylacetyl, imidazolylacetyl, furylacetyl, tetrazolylacetyl, thiazolylacetyl, thiadiazolylacetyl, thienylpropionyl, thiadiazolyl- propionyl, and the like.
- acyl groups may be further substituted with one or more suitable substituents such as lower alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, etc.), halogen (e.g. chlorine, bromine, iodine, fluorine), lower alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentyloxy, hexyloxy, etc.), lower alkylthio (e.g.
- lower alkyl e.g. methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, etc.
- halogen e.g. chlorine, bromine, iodine, fluorine
- lower alkoxy e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentyloxy, he
- acyl having such substituent(s) may be mono (or di or tri)halo(lower)-alkanoyl (e.g. chloroacetyl, bromoacetyl, dichloroacetyl, trifluoroacetyl, etc.), mono (or di or tri)halo(lower)-alkoxycarbonyl (e.g.
- chloromethoxycarbonyl dichloro- methoxycarbonyl, 2,2,2-tri-chloroethoxycarbonyl, etc.
- nitro (or halo or lower alkoxy)phenyl(lower)alkoxycarbonyl e.g. nitrobenzyloxycarbonyl, chlorobenzyloxycarbonyl, methoxybenzyloxycarbonyl, etc.
- lower alkoxyaroyl such as lower alkoxybenzoyl (e.g. anisoyl, ethoxybenzoyl, etc.), and the like.
- Suitable “di(lower)alkylaminomethylene” may include dimethylaminomethylene, diethylaminomethylene, dipropylaminomethylene, and the like.
- the preferred embodiments of "mono- or di-substituted amino" among the above may be mono- or di-(lower)alkylamino, mono- or di-(lower)alkanesulfonamido, mono- or di-(lower)alkanamido, mono- or di-(lower)alkoxalylamino, mono- or di-aroylamino optionally substituted by lower alkoxy, mono- or di-(C 3 -C 7 )cycloalkanamido, N'-(lower)alkylureido, N-(lower)alkyl(lower)alkanamido, [N,N-di(lower)alkylamino]methyleneamino, and the like.
- Suitable "halogen" for R may include fluorine, chlorine, bromine and iodine, in which the most preferred one is chlorine.
- Suitable "lower alkyl” for R may include the same ones as those exemplified for "lower alkyl” as the substituent in R 1 .
- Suitable "aryl” for R 2 may include phenyl, tolyl, xylyl, cumenyl, mesityl, naphthyl and the like, in which the most preferred one is phenyl.
- Suitable "ar(lower)alkyl optionally substituted by halogen" for R 3 may include mono(or di or tri)-phenyl(lower)alkyl (e.g. benzyl, phenethyl, benzhydryl, trityl, etc.), mono (or di or tri)phenyl (lower) alkyl substituted by 1 to 5 halogen atom(s) as exemplified for R 2 (e.g.
- chlorobenzyl bromobenzyl, fluorobenzyl, chlorophenethyl, dichlorobenzyl, trichlorobenzyl, tetrachlorobenzyl, pentachlorobenzyl, chlorobenzhydryl, etc.), and the like, in which the preferred one is diphenyl(lower)alkyl optionally substituted by 1 to 5 halogen atom(s).
- Suitable "lower alkylene optionally interrupted by a sulfur atom" for A may include lower alkylene (e.g. methylene, ethylene, propylene, trimethylene, tetramethylene, pentamethylene, etc.), lower alkylene interrupted by a sulfur atom of the formula: -A 1 -S-A 2 -, in which A 1 and A 2 are each lower alkylene as exemplified above.
- lower alkylene e.g. methylene, ethylene, propylene, trimethylene, tetramethylene, pentamethylene, etc.
- Suitable "C 1 -C 3 alkylene" for Y may include methylene, ethylene, propylene, trimethylene and the like, and the most preferred one is ethylene.
- Suitable pharmaceutically acceptable salts of the object compounds (I) are conventional non-toxic salts and may include an acid addition salt such as an inorganic acid addition salt (e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.), an organic acid addition salt (e.g. oxalate, maleate, lactate, tartrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.) or a salt with an amino acid (e.g. aspartic acid, glutamic acid, etc.), a salt with a base such as alkali metal salt (e.g. sodium salt, potassium salt, etc.), and the like.
- an acid addition salt such as an inorganic acid addition salt (e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.), an organic acid addition salt (e.g. oxalate, maleate, lactate, tartrate, fum
- the object compounds (I) of the present invention can be prepared by the following processes.
- Suitable protective group in the "protected amino" for may include an acyl group as exemplified for the acyl group as a substituent in R 1 .
- Suitable acyl moiety in the "acylamino" for may include the same ones as the above.
- Suitable "acid residue" for Z 1 , Z 2 and Z 3 may include halogen (e.g. chlorine, bromine, iodine, etc.), azido, acyloxy (e.g. benzenesulfonyloxy, tosyloxy, etc.) and the like.
- halogen e.g. chlorine, bromine, iodine, etc.
- azido e.g. chlorine, bromine, iodine, etc.
- acyloxy e.g. benzenesulfonyloxy, tosyloxy, etc.
- the compound (I) or its salt can be prepared by reacting a compound (II) or its salt with a compound (III) or its salt.
- Suitable salt of the compounds (II) and (III) may be ones as exemplified before.
- This reaction can preferably be carried out in the presence of an organic or inorganic base such as tri(lower)alkylamine (e.g. trimethylamine, triethylamine, etc.), N,N-di(lower)alkyl arylamine (e.g. N,N-dimethylaniline, etc.), N,N-di(lower)alkyl ar(lower)alkylamine (e.g.
- an organic or inorganic base such as tri(lower)alkylamine (e.g. trimethylamine, triethylamine, etc.), N,N-di(lower)alkyl arylamine (e.g. N,N-dimethylaniline, etc.), N,N-di(lower)alkyl ar(lower)alkylamine (e.g.
- alkali metal acetate e.g. sodium acetate, potassium acetate, etc.
- alkali metal lower alkoxide e.g. sodium methoxide, sodium ethoxide, potassium tert-butoxide, etc.
- alkali metal hydride e.g. sodium hydride, potassium hydride, etc.
- alkali metal hydroxide e.g.
- alkaline earth metal hydroxide e.g. magnesium hydroxide, calcium hydroxide, etc.
- alkali metal carbonate e.g. sodium carbonate, potassium carbonate, etc.
- alkaline earth metal carbonate e.g. magnesium carbonate, calcium carbonate, etc.
- alkali metal bicarbonate e.g. sodium bicarbonate potassium bicarbonate, etc.
- This reaction can also be carried out in the presence of a reaction stimulator such as metal halide (e.g. sodium iodide, potassium iodide, etc.) or the like.
- a reaction stimulator such as metal halide (e.g. sodium iodide, potassium iodide, etc.) or the like.
- This reaction is usually carried out in a conventional solvent such as methanol, benzene, acetone, dioxane, N,N-dimethylformamide or any other solvent which does not adversely influence the reaction.
- a conventional solvent such as methanol, benzene, acetone, dioxane, N,N-dimethylformamide or any other solvent which does not adversely influence the reaction.
- the reaction temperature is not critical, and the reaction is usually carried out under warming or heating.
- the compound (1-2) or its salt can be prepared by subjecting a compound (I-I) to removing reaction of the amino-protective group in .
- Suitable method for this reaction may include hydrolysis, hydrogenolysis, and the like.
- reaction is conducted by hydrolysis, it is preferably carried out in the presence of an acid or a base.
- Suitable acid may include an inorganic acid (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, etc.), an organic acid (e.g. formic acid, acetic acid, trifluoroacetic acid, propionic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.), and the like.
- an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, etc.
- an organic acid e.g. formic acid, acetic acid, trifluoroacetic acid, propionic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.
- Suitable base may include ones as exemplified in the explanation of Process 1.
- the hydrolysis is usually carried out in a conventional solvent such as water, methanol, ethanol, tetrahydrofuran, dioxane, N,N-dimethylformamide or any other solvent which does not adversely influence the reaction.
- a conventional solvent such as water, methanol, ethanol, tetrahydrofuran, dioxane, N,N-dimethylformamide or any other solvent which does not adversely influence the reaction.
- the reaction temperature is not critical, and the reaction is usually carried out at ambient temperature or under warming or heating.
- suitable catalyst may be palladium catalyst (e.g. palladium on charcoal, palladium on barium sulfate, colloidal palladium, spongy palladium, etc.), platinum catalyst (e.g. platinum plate, platinum wire, platinum black, spongy platinum etc.), and the like.
- palladium catalyst e.g. palladium on charcoal, palladium on barium sulfate, colloidal palladium, spongy palladium, etc.
- platinum catalyst e.g. platinum plate, platinum wire, platinum black, spongy platinum etc.
- the catalytic reduction is usually carried out in a conventional solvent such as water, methanol, ethanol, propanol or any other solvent which does not adversely influence the reaction.
- the reaction temperature is not critical, and the reaction is usually carried out at ambient temperature or under warming.
- the compound (1-3) or its salt can be prepared by reacting a compound (I-2) or its salt with an acylating agent.
- Suitable acylating agent may include an acid and its reactive derivative containing the acyl group as exemplified before.
- Suitable example of the reactive derivative may be acid halide (e.g. acid chloride, acid bromide, etc.), acid anhydride such as acid anhydride with lower alkanoic acid (e.g. acetic acid, etc.) or mono(lower)-alkyl carbonate (e.g. monoethyl carbonate, etc.), activated amide (e.g. amide with pyrazole, imidazole, 4-methylimidazole, etc.), activated ester (e.g. cyanomethyl ester, methoxymethyl ester, p-nitrophenyl ester, etc.), and the like.
- acid halide e.g. acid chloride, acid bromide, etc.
- acid anhydride such as acid anhydride with lower alkanoic acid (e.g. acetic acid, etc.) or mono(lower)-alkyl carbonate (e.g. monoethyl carbonate, etc.)
- activated amide e.g.
- the reaction can be carried out in the presence of an organic or inorganic base as exemplified in the explanation of Process 1.
- the reaction can preferably be carried out in the presence of a condensing agent such as a carbodiimide compound (e.g., N,N'-dicyclohexylcarbodiimide, N-cyclohexyl-N'-morpholinoethylcarbodiimide, N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide, N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide, N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide, etc.), a ketenimine compound (e.g., N,N'-carbonylbis(2-methylimidazole),pentamethyleneketene-N-cyclohexylimine, diphenylketene-N-
- a condensing agent such as a carbodiimide
- This reaction is usually carried out in a conventional solvent such as methylene chloride, chloroform, ethylene chloride, acetone, methanol, ethanol, tetrahydrofuran, pyridine, N,N-dimethylformamide or any other solvent which does not adversely influence the reaction.
- a conventional solvent such as methylene chloride, chloroform, ethylene chloride, acetone, methanol, ethanol, tetrahydrofuran, pyridine, N,N-dimethylformamide or any other solvent which does not adversely influence the reaction.
- the reaction temperature is not critical, and the reaction is usually carried out under cooling or at ambient temperature.
- the compound (1-4) or its salt can be prepared by reacting a compound (IV) or its salt with a compound (V) or its salt.
- Suitable salt of the compound (IV) may be ones as exemplified before and that of the compound (V) may be an acid addition salt as exemplified before.
- reaction can be carried out in substantially the same manner as that of Process 1, and therefore, the reaction mode and reaction conditions (e.g. solvent, reaction temperature, etc.) can be referred to the explanation of Process 1.
- reaction mode and reaction conditions e.g. solvent, reaction temperature, etc.
- the object compounds (I) obtained in the above Processes 1 to 4 can be isolated and purified in a conventional manner, for example, extraction, precipitation, fractional chromatography, fractional crystallization, recrystallization, and the like.
- the object compounds (I) thus prepared can be transformed into optional pharmaceutically acceptable salt by a conventional method, if desired.
- Suitable "[N,N-di(lower)alkylaminomethylene]amino” for , “lower alkyl” for and “halogen” for X 1 and X 2 may be the same ones as those exemplified before, respectively.
- the compound (VII) can be prepared by reacting a compound (VI) with diazomethane and then with hydrogen halide.
- Suitable “hydrogen halide” may include hydrogen chloride, hydrogen bromide, and the like.
- the reaction is usually carried out in a solvent such as diethyl ether or any other solvent which does not adversely influence the reaction.
- the reaction temperature is not critical, and the reaction is usually carried out under cooling or at ambient temperature.
- the compound (IX) can be prepared by reacting a compound (VIII) with hydrogen sulfide.
- the reaction is preferably carried out in the presence of a base as exemplified in the explanation of Process 1.
- the reaction is usually carried out in a solvent such as pyridine or any other solvent which does not adversely influence the reaction.
- the reaction temperature is not critical, and the reaction is usually carried out at ambient temperature or under warming or heating.
- the compound (II-1) or its salt can be prepared by reacting a compound (VII) with a compound (IX).
- This reaction is usually carried out in a solvent such as water, methanol, ethanol, propanol or any other solvent which does not adversely influence the reaction.
- the reaction temperature is not critical, and the reaction is usually carried out under warming or heating.
- the compound (II-2) or its salt can be prepared by reacting a compound (X) with a compound (IX).
- This reaction can be carried out in substantially the same manner as that of Process C, and therefore, the reaction mode and reaction conditions (e.g. solvent, reaction temperature, etc.) can be referred to the explanation of Process C.
- reaction mode and reaction conditions e.g. solvent, reaction temperature, etc.
- the compound (II-4) or its salt can be prepared by reacting a compound (II-3) or its salt with an acylating agent.
- Suitable acylating agent may be the same as those exemplified in the explanation of Process 3.
- reaction can be carried out in substantially the same manner as that of Process 3, and therefore, the reaction mode and reaction conditions (e.g. solvent, reaction temperature, etc.) can be referred to the explanation of Process 3.
- reaction mode and reaction conditions e.g. solvent, reaction temperature, etc.
- the compound (II-5) can be prepared by reacting - a compound (II-3) or its salt with Vilsmeier Reagent.
- Vilsmeier Reagent used in this process can be prepared in a conventional manner, for example, by reacting N,N-di(lower)alkylformamide with a halogenating agent such as phosphorus oxychloride, phosphorus trihalide (e.g. phosphorus tribromide, phosphorus trichloride, etc.), phosphorus pentahalide (e.g. phosphorus pentachloride, etc.), lower alkanesulfonyl halide (e.g. methanesulfonyl chloride, ethanesulfonyl chloride, etc.) or the like.
- a halogenating agent such as phosphorus oxychloride, phosphorus trihalide (e.g. phosphorus tribromide, phosphorus trichloride, etc.), phosphorus pentahalide (e.g. phosphorus pentachloride, etc.), lower alkanesulfonyl hal
- the reaction is usually carried out in the presence of pyridine.
- the reaction temperature is not critical, and the reaction is usually carried out at a temperature range from cooling to heating.
- the object compounds (I) and pharmaceutically acceptable salts thereof obtained according to the processes of this invention have potent and long lasting antiallergic activity and can be used therapeutically as well as prophylactically as antiallergic agents for relieving or inhibiting allergic symptoms of human being and animals.
- the inhibitory effect of the test compounds was determined from the number of surviving animals more than 2 hours after spray of the antigen.
- the object compounds (I) of the present invention are useful for the antiallergic medicines.
- the object compounds (I) of the present invention and pharmaceutically acceptable salts thereof are used in a form of the conventional pharmaceutical preparation in admixture with a conventional pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient which is suitable for oral, parenteral or external administration.
- a conventional pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient which is suitable for oral, parenteral or external administration.
- the pharmaceutical preparation may be compounded in a solid form such as capsule, tablet, dragee, ointment or suppository, or in a liquid form such as solution, suspension or emulsion. If needed, there may be included in the above preparation auxiliary substance, stabilizing agent, wetting or emulsifying agent, buffer or any other commonly used additives.
- the effective ingredient may usually be administered with a unit dose of 1 mg/kg to 500 mg/kg., 1 to 4 times a day.
- the above dosage may be increased or decreased according to age, weight and conditions of the patient or the administering method.
- 2-Amino-4-[2-14-(4-chlorobenzhydryl)piperazin-1-yl ⁇ ethyl]thiazole trihydrochloride (2.65 g) was obtained by hydrolyzing 2-acetamido-4-[2- ⁇ 4-(4-chlorobenzhydryl)piperazin-1-yl ⁇ ethyl]thiazole (5.0 g) with conc. hydrochloric acid (10 ml) according to a similar manner to that of Example 21, mp 180-185°C (dec.).
- the extract was washed with an aqueous solution of sodium bicarbonate and water, dried over anhydrous magnesium sulfate, and then evaporated to give an amorphous product (1.7 g), which was chromatographed on silica gel (20 g) using a mixture of chloroform and methanol (20:1 by volume) as an eluent.
- the eluates containing the desired compound were collected and evaporated to give a residue, which was transformed into fumarate in a conventional manner.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
- R2 is hydrogen, halogen, lower alkyl or aryl,
- R3 is ar(lower)alkyl optionally substituted by halogen,
- A is lower alkylene optionally interrupted by a sulfur atom, and
- Y is C1-C3 alkylene, and their pharmaceutically - acceptable
Description
- The present invention relates to novel thiazole derivatives and pharmaceutically acceptable salts thereof. More particularly, it relates to novel thiazole derivatives and pharmaceutically acceptable salts thereof which have antiallergic activities, to processes for the preparation thereof, to pharmaceutical composition comprising the same, and to a method of using the same therapeutically in the treatment of allergic symptoms in human being and animals.
- Accordingly, it is one object of the present invention to provide thiazole derivatives and pharmaceutically acceptable salts thereof, which are useful as antiallergic agents.
- Another object of the present invention is to provide processes for the preparation of thiazole derivatives and pharmaceutically acceptable salts thereof.
- A further object of the present invention is to provide pharmaceutical composition comprising, as an active ingredient, said thiazole derivative or its pharmaceutically acceptable salt.
- Still further object of the present invention is to provide a method of using said thiazole derivative or its pharmaceutically acceptable salt in the treatment of allergic symptoms in human being and animals.
-
- wherein R1 is hydrogen, amino, or mono- or di-substituted amino, in which the substituent is selected from lower alkyl, acyl and di(lower)-alkylaminomethylene,
- R2 is hydrogen, halogen, lower alkyl or aryl,
- R3 is ar(lower)alkyl optionally substituted by halogen,
- A is lower alkylene optionally interrupted by a sulfur atom, and
- Y is C1-C3alkylene.
- With regard to the object compounds of the above formula (I), it is to be understood that the compounds (I) represent inclusively all of the possible optical and/or geometrical isomers due to the asymmetric carbon atom and carbon-nitrogen double bond (; C=N-) in the molecule of the compounds (I), and accordingly such optical and/or geometrical isomers are also included within the scope of the present invention.
- As to the various definitions as indicated above, suitable illustrations and examples are explained in detail as follows.
- The term "lower" is intended to mean 1 to 6 carbon atom(s), unless otherwise indicated.
- In the definition of "mono- or di-substituted amino, in which the substituent is selected from lower alkyl, acyl and di(lower)alkylaminomethylene" for R1, suitable examples of each substituent are as follows.
- Suitable "lower alkyl" may include straight or branched one such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl and the like, in which the preferred one is Cl-C4alkyl.
- Suitable "acyl" may include an aliphatic acyl, an aromatic acyl, a heterocyclic acyl and an aliphatic acyl substituted with aromatic or heterocyclic group(s).
- The aliphatic acyl may include saturated or unsaturated, acyclic or cyclic ones, such as lower alkanoyl (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, etc.), lower alkanesulfonyl (e.g. methanesulfonyl, ethanesulfonyl, propanesulfonyl, butanesulfonyl, etc.), lower alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, tert- butoxycarbonyl, etc.), N-lower alkylcarbamoyl (e.g. N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, etc.), lower alkoxalyl (e.g. methoxalyl, ethoxalyl, propoxalyl, etc.), lower alkenoyl (e.g. acryloyl, methacryloyl, crotonoyl, etc.), (C3-C7}-cycloalkanecarbonyl (e.g. cyclohexanecarbonyl, etc.), and the like.
- The aromatic acyl may include aroyl (e.g. benzoyl, toluoyl, xyloyl, etc.), arenesulfonyl (e.g. benzenesulfonyl, tosyl, etc.), and the like.
- The heterocyclic acyl may include heterocycle- carbonyl (e.g. furoyl, thenoyl, nicotinoyl, isonicotinoyl, thiazolylcarbonyl, thiadiazolylcarbonyl, tetrazolylcarbonyl, etc.), and the like.
- The aliphatic acyl substituted with aromatic group(s) may include phenyl(lower)alkanoyl (e.g. phenylacetyl, phenylpropionyl, phenylhexanoyl, etc.), phenyl(lower)-alkoxycarbonyl (e.g. benzyloxycarbonyl, phenethyloxycarbonyl, etc.), phenoxy(lower)alkanoyl (e.g. phenoxyacetyl, phenoxypropionyl, etc.), and the like.
- The aliphatic acyl substituted with heterocyclic group(s) may include thienylacetyl, imidazolylacetyl, furylacetyl, tetrazolylacetyl, thiazolylacetyl, thiadiazolylacetyl, thienylpropionyl, thiadiazolyl- propionyl, and the like.
- These acyl groups may be further substituted with one or more suitable substituents such as lower alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, etc.), halogen (e.g. chlorine, bromine, iodine, fluorine), lower alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentyloxy, hexyloxy, etc.), lower alkylthio (e.g. methylthio, ethylthio, propylthio, isopropylthio, butylthio, pentylthio, hexylthio, etc.), nitro,and the like, and preferable acyl having such substituent(s) may be mono (or di or tri)halo(lower)-alkanoyl (e.g. chloroacetyl, bromoacetyl, dichloroacetyl, trifluoroacetyl, etc.), mono (or di or tri)halo(lower)-alkoxycarbonyl (e.g. chloromethoxycarbonyl, dichloro- methoxycarbonyl, 2,2,2-tri-chloroethoxycarbonyl, etc.), nitro (or halo or lower alkoxy)phenyl(lower)alkoxycarbonyl (e.g. nitrobenzyloxycarbonyl, chlorobenzyloxycarbonyl, methoxybenzyloxycarbonyl, etc.), lower alkoxyaroyl such as lower alkoxybenzoyl (e.g. anisoyl, ethoxybenzoyl, etc.), and the like.
- Suitable "di(lower)alkylaminomethylene" may include dimethylaminomethylene, diethylaminomethylene, dipropylaminomethylene, and the like.
- The preferred embodiments of "mono- or di-substituted amino" among the above may be mono- or di-(lower)alkylamino, mono- or di-(lower)alkanesulfonamido, mono- or di-(lower)alkanamido, mono- or di-(lower)alkoxalylamino, mono- or di-aroylamino optionally substituted by lower alkoxy, mono- or di-(C3-C7)cycloalkanamido, N'-(lower)alkylureido, N-(lower)alkyl(lower)alkanamido, [N,N-di(lower)alkylamino]methyleneamino, and the like.
- Suitable "halogen" for R may include fluorine, chlorine, bromine and iodine, in which the most preferred one is chlorine.
- Suitable "lower alkyl" for R may include the same ones as those exemplified for "lower alkyl" as the substituent in R 1.
- Suitable "aryl" for R2 may include phenyl, tolyl, xylyl, cumenyl, mesityl, naphthyl and the like, in which the most preferred one is phenyl.
- Suitable "ar(lower)alkyl optionally substituted by halogen" for R3 may include mono(or di or tri)-phenyl(lower)alkyl (e.g. benzyl, phenethyl, benzhydryl, trityl, etc.), mono (or di or tri)phenyl (lower) alkyl substituted by 1 to 5 halogen atom(s) as exemplified for R2 (e.g. chlorobenzyl, bromobenzyl, fluorobenzyl, chlorophenethyl, dichlorobenzyl, trichlorobenzyl, tetrachlorobenzyl, pentachlorobenzyl, chlorobenzhydryl, etc.), and the like, in which the preferred one is diphenyl(lower)alkyl optionally substituted by 1 to 5 halogen atom(s).
- Suitable "lower alkylene optionally interrupted by a sulfur atom" for A may include lower alkylene (e.g. methylene, ethylene, propylene, trimethylene, tetramethylene, pentamethylene, etc.), lower alkylene interrupted by a sulfur atom of the formula: -A1-S-A2-, in which A1 and A2 are each lower alkylene as exemplified above.
- Suitable "C1-C3alkylene" for Y may include methylene, ethylene, propylene, trimethylene and the like, and the most preferred one is ethylene.
- Suitable pharmaceutically acceptable salts of the object compounds (I) are conventional non-toxic salts and may include an acid addition salt such as an inorganic acid addition salt (e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.), an organic acid addition salt (e.g. oxalate, maleate, lactate, tartrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.) or a salt with an amino acid (e.g. aspartic acid, glutamic acid, etc.), a salt with a base such as alkali metal salt (e.g. sodium salt, potassium salt, etc.), and the like.
-
- wherein R 1, R 2, R3, A, A1, A2 and Y are each as defined above,
-
-
- Z1 is an acid residue, and
- one of Z2 and Z3 is mercapto and the other is an acid residue.
-
-
- Suitable "acid residue" for Z1, Z2 and Z3 may include halogen (e.g. chlorine, bromine, iodine, etc.), azido, acyloxy (e.g. benzenesulfonyloxy, tosyloxy, etc.) and the like.
- The aforementioned processes for preparing the object compounds (I) of the present invention are explained in detail in the following.
- The compound (I) or its salt can be prepared by reacting a compound (II) or its salt with a compound (III) or its salt.
- Suitable salt of the compounds (II) and (III) may be ones as exemplified before.
- This reaction can preferably be carried out in the presence of an organic or inorganic base such as tri(lower)alkylamine (e.g. trimethylamine, triethylamine, etc.), N,N-di(lower)alkyl arylamine (e.g. N,N-dimethylaniline, etc.), N,N-di(lower)alkyl ar(lower)alkylamine (e.g. N,N-dimethyl benzylamine, etc.), pyridine, picoline, 1,5-diazabicyclo[4,3,0]non-5-ene, 1,4-diazabicyclo[2,2,2]octane, 1,5-diazabicyclo-[5,4,0]undecene-5, alkali metal acetate (e.g. sodium acetate, potassium acetate, etc.), alkali metal lower alkoxide (e.g. sodium methoxide, sodium ethoxide, potassium tert-butoxide, etc.), alkali metal hydride (e.g. sodium hydride, potassium hydride, etc.), alkali metal hydroxide (e.g. sodium hydroxide, potassium hydroxide, etc.), alkaline earth metal hydroxide (e.g. magnesium hydroxide, calcium hydroxide, etc.), alkali metal carbonate (e.g. sodium carbonate, potassium carbonate, etc.), alkaline earth metal carbonate (e.g. magnesium carbonate, calcium carbonate, etc.), alkali metal bicarbonate (e.g. sodium bicarbonate potassium bicarbonate, etc.), or the like.
- This reaction can also be carried out in the presence of a reaction stimulator such as metal halide (e.g. sodium iodide, potassium iodide, etc.) or the like.
- This reaction is usually carried out in a conventional solvent such as methanol, benzene, acetone, dioxane, N,N-dimethylformamide or any other solvent which does not adversely influence the reaction.
- The reaction temperature is not critical, and the reaction is usually carried out under warming or heating.
-
- Suitable method for this reaction may include hydrolysis, hydrogenolysis, and the like.
- In case that the reaction is conducted by hydrolysis, it is preferably carried out in the presence of an acid or a base.
- Suitable acid may include an inorganic acid (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, etc.), an organic acid (e.g. formic acid, acetic acid, trifluoroacetic acid, propionic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.), and the like.
- Suitable base may include ones as exemplified in the explanation of Process 1.
- The hydrolysis is usually carried out in a conventional solvent such as water, methanol, ethanol, tetrahydrofuran, dioxane, N,N-dimethylformamide or any other solvent which does not adversely influence the reaction.
- The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature or under warming or heating.
- In case that the removing reaction is conducted by hydrogenolysis, it is carried out by conventional catalytic reduction, and suitable catalyst may be palladium catalyst (e.g. palladium on charcoal, palladium on barium sulfate, colloidal palladium, spongy palladium, etc.), platinum catalyst (e.g. platinum plate, platinum wire, platinum black, spongy platinum etc.), and the like.
- The catalytic reduction is usually carried out in a conventional solvent such as water, methanol, ethanol, propanol or any other solvent which does not adversely influence the reaction.
- The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature or under warming.
- The compound (1-3) or its salt can be prepared by reacting a compound (I-2) or its salt with an acylating agent.
- Suitable acylating agent may include an acid and its reactive derivative containing the acyl group as exemplified before.
- Suitable example of the reactive derivative may be acid halide (e.g. acid chloride, acid bromide, etc.), acid anhydride such as acid anhydride with lower alkanoic acid (e.g. acetic acid, etc.) or mono(lower)-alkyl carbonate (e.g. monoethyl carbonate, etc.), activated amide (e.g. amide with pyrazole, imidazole, 4-methylimidazole, etc.), activated ester (e.g. cyanomethyl ester, methoxymethyl ester, p-nitrophenyl ester, etc.), and the like.
- The reaction can be carried out in the presence of an organic or inorganic base as exemplified in the explanation of Process 1.
- In case that the acylating agent is used in a form of free acid, the reaction can preferably be carried out in the presence of a condensing agent such as a carbodiimide compound (e.g., N,N'-dicyclohexylcarbodiimide, N-cyclohexyl-N'-morpholinoethylcarbodiimide, N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide, N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide, N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide, etc.), a ketenimine compound (e.g., N,N'-carbonylbis(2-methylimidazole),pentamethyleneketene-N-cyclohexylimine, diphenylketene-N-cyclohexylimine, etc.); an olefinic or acetylenic ether compound (e.g., ethoxyacetylene S-chlorovinylethyl ether), a sulfonic acid ester of N-hydroxybenzotriazole derivative (e.g., 1-(4-chlorobenzenesulfonyloxy)-6-chloro-lH-benzotriazole, etc.), a phosphorus compound (e.g., trialkyl phosphite, ethyl polyphosphate, isopropyl polyphosphate, phosphoryl chloride, phosphorus trichloride, triphenylphosphine, etc.), thionyl chloride, oxalyl chloride, N-ethylbenzisoxazolium salt, N-ethyl-5-phenylisoxazolium-3'-sulfonate, a reagent (referred to as so-called "Vilsmeier reagent") formed by the reaction of an amide compound (e.g. dimethylformamide, diethylformamide,-etc.r with a
halogen compound (e.g. thionyl chloride, phosphoryl chloride, phosgene, etc.), and the like. - This reaction is usually carried out in a conventional solvent such as methylene chloride, chloroform, ethylene chloride, acetone, methanol, ethanol, tetrahydrofuran, pyridine, N,N-dimethylformamide or any other solvent which does not adversely influence the reaction.
- The reaction temperature is not critical, and the reaction is usually carried out under cooling or at ambient temperature.
- The compound (1-4) or its salt can be prepared by reacting a compound (IV) or its salt with a compound (V) or its salt.
- Suitable salt of the compound (IV) may be ones as exemplified before and that of the compound (V) may be an acid addition salt as exemplified before.
- This reaction can be carried out in substantially the same manner as that of Process 1, and therefore, the reaction mode and reaction conditions (e.g. solvent, reaction temperature, etc.) can be referred to the explanation of Process 1.
- The object compounds (I) obtained in the above Processes 1 to 4 can be isolated and purified in a conventional manner, for example, extraction, precipitation, fractional chromatography, fractional crystallization, recrystallization, and the like.
- The object compounds (I) thus prepared can be transformed into optional pharmaceutically acceptable salt by a conventional method, if desired.
-
- wherein R1,
-
-
- X1 and X2 are each halogen.
-
- The processes for preparing the starting compounds are explained in more detail in the following.
- The compound (VII) can be prepared by reacting a compound (VI) with diazomethane and then with hydrogen halide.
- Suitable "hydrogen halide" may include hydrogen chloride, hydrogen bromide, and the like.
- The reaction is usually carried out in a solvent such as diethyl ether or any other solvent which does not adversely influence the reaction.
- The reaction temperature is not critical, and the reaction is usually carried out under cooling or at ambient temperature.
- The compound (IX) can be prepared by reacting a compound (VIII) with hydrogen sulfide.
- The reaction is preferably carried out in the presence of a base as exemplified in the explanation of Process 1.
- The reaction is usually carried out in a solvent such as pyridine or any other solvent which does not adversely influence the reaction.
- The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature or under warming or heating.
- The compound (II-1) or its salt can be prepared by reacting a compound (VII) with a compound (IX).
- This reaction is usually carried out in a solvent such as water, methanol, ethanol, propanol or any other solvent which does not adversely influence the reaction.
- The reaction temperature is not critical, and the reaction is usually carried out under warming or heating.
- The compound (II-2) or its salt can be prepared by reacting a compound (X) with a compound (IX).
- This reaction can be carried out in substantially the same manner as that of Process C, and therefore, the reaction mode and reaction conditions (e.g. solvent, reaction temperature, etc.) can be referred to the explanation of Process C.
- The compound (II-4) or its salt can be prepared by reacting a compound (II-3) or its salt with an acylating agent.
- Suitable acylating agent may be the same as those exemplified in the explanation of Process 3.
- This reaction can be carried out in substantially the same manner as that of Process 3, and therefore, the reaction mode and reaction conditions (e.g. solvent, reaction temperature, etc.) can be referred to the explanation of Process 3.
- The compound (II-5) can be prepared by reacting - a compound (II-3) or its salt with Vilsmeier Reagent.
- Vilsmeier Reagent used in this process can be prepared in a conventional manner, for example, by reacting N,N-di(lower)alkylformamide with a halogenating agent such as phosphorus oxychloride, phosphorus trihalide (e.g. phosphorus tribromide, phosphorus trichloride, etc.), phosphorus pentahalide (e.g. phosphorus pentachloride, etc.), lower alkanesulfonyl halide (e.g. methanesulfonyl chloride, ethanesulfonyl chloride, etc.) or the like.
- The reaction is usually carried out in the presence of pyridine.
- The reaction temperature is not critical, and the reaction is usually carried out at a temperature range from cooling to heating.
- The object compounds (I) and pharmaceutically acceptable salts thereof obtained according to the processes of this invention have potent and long lasting antiallergic activity and can be used therapeutically as well as prophylactically as antiallergic agents for relieving or inhibiting allergic symptoms of human being and animals.
-
- Compound A : 4-(4-Benzhydrylpiperazin-l-ylmethyl)-2- methanesulfonamidothiazole
- Compound B : 4-(4-Benzhydrylpiperazin-1-ylmethyl)-2-ethanesulfonamidothiazole
- Compound C : 4-(4-Benzhydrylpiperazin-l-ylmethyl)-2-propanesulfonamidothiazole
- Compound D : 4-[3-(4-Benzhydrylpiperazin-1-yl)-propyl]-2-acetamidothiazole
-
- (1) Preparation of rabbit antiserum against egg albumin Equal volumes of a saline solution of egg albumin (200 mg/ml) and of Freund's Complete Ajuvant were mixed and emulsified. Each male New Zealand white strain rabbits, each weighing 2 to 2.5 kg., received an intramuscular injection of 0.5 ml of the emulsion in the left and right thigh regions. One week later, they received an intradermal injection of 0.25 ml.of a saline solution of egg albumin (concentration : 20 mg/ml) in the different four sites of the dorsal skin surface three times every other week. Blood samples were collected from the carotid artery one week after the last injection.
- (2) Determination of Passive Cutaneous Anaphylaxis (PCA) titer The level of anaphylactic anti-egg albumin antibodies in pools of sera were determined by passive cutaneous anaphylaxis (PCA) reactions using shaven Hartley strain test guinea-pigs. Antiserum was serially diluted (two fold) in saline and 0.1 ml of each antiserum dilution were injected intradermally into the dorsal skin surface of the test guinea-pigs. 24 hours after intradermal sensitization, Egg albumin-specific PCA reactions were elicited by intravenous injection of 10 mg of egg albumin in 1 ml of 1% Evans blue dye dissolved in saline. Reactions were read and recorded as the highest dilution of serum evoking threshold PCA reactivity (5 mm diameter).
- (3) Antagonism to anaphylactic asthma in guinea-pigs Male Hartley stain guinea-pigs, weighing 305 to 400 g, were used. Animals were sensitized by an intravenous injection of rabbit antiserum against egg albumin (4000 PCA titer) with 0.5 ml/animal. After 24 hours, animals were placed individually in a plastic chamber of 5.3 liter volume. An aerosol of 5% egg albumin solution was sprayed in the chamber at a rate of 0.16 ml/min with a commercial nebulizer. The test compounds were given to the animals orally 30 minutes before the challenge with the egg albumin solution. Each dose group consisted of 3 or 5 animals.
-
- As being apparent from the above test results, the object compounds (I) of the present invention are useful for the antiallergic medicines.
- For therapeutic administration, the object compounds (I) of the present invention and pharmaceutically acceptable salts thereof are used in a form of the conventional pharmaceutical preparation in admixture with a conventional pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient which is suitable for oral, parenteral or external administration.
- The pharmaceutical preparation may be compounded in a solid form such as capsule, tablet, dragee, ointment or suppository, or in a liquid form such as solution, suspension or emulsion. If needed, there may be included in the above preparation auxiliary substance, stabilizing agent, wetting or emulsifying agent, buffer or any other commonly used additives.
- The effective ingredient may usually be administered with a unit dose of 1 mg/kg to 500 mg/kg., 1 to 4 times a day. However, the above dosage may be increased or decreased according to age, weight and conditions of the patient or the administering method.
- The following examples are given only for the purpose of illustrating the present invention in more detail. (continued to the next page) Preparation of the starting compounds
-
- (1) To a suspension of N-methyl-N-nitrosourea (25.0 g) in diethyl ether (130 ml) was added dropwise 40% aqueous solution of potassium hydroxide (52 ml) below 5°C, and the separated organic layer was dried over potassium hydroxide to prepare a solution of diazomethane in diethyl ether. To this solution was added dropwise a solution of 3-chloropropionyl chloride (8.0 g) in diethyl ether (40 ml) below -5°C over a period of 20 minutes with stirring, and the stirring was continued at the same temperature for 2 hours. After hydrogen chloride was introduced into the reaction mixture for about an hour, nitrogen was additionally introduced thereinto for about half an hour, followed by concentration. After dissolving it in diethyl ether and drying over anhydrous magnesium sulfate, the solution was evaporated to dryness to give an oil, which was purified by distillation to obtain 1,4-dichloro-2-butanone (5.6 g), bp 92.5-94°C/20 mmHg. IR cm-1 (Film) : 1725, 1400, 1298, 1080, 960, 772 NMR 6ppm (CC14) : 3.18 (2H, t, J=10.0Hz), 3.84 (2H, t, J=lO.OHz), 4.17 (2H, s)
- (2) 5.4 g of this product was added to an aqueous solution (52 ml) of thiourea (2.92 g) and heated at 100°C for half an hour. After concentration under reduced pressure, the residue was neutralized with 1N aqueous solution of sodium hydroxide, followed by extracting with diethyl ether. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to obtain an oil (5.9 g) of 2-amino-4-(2-chloroethyl)thiazole.
- (3) A solution of this compound in acetic anhydride (30 ml) was refluxed under heating for 1.5 hours, followed by concentration. The residue was recrystallized from benzene to obtain white crystals (5.45 g) of 2-acetamido-4-(2-chloroethyl)thiazole, mp 161-163°C. IR cm-1 (Nujol) : 3160, 1633, 1320, 1000, 942, 724 NMR 6ppm (DMSO-d6) : 2.13 (3H, s), 3.05 (2H, t, J=7.0Hz), 3.89 (2H, t, J=7.0Hz), 6.9 (lH, s), 12.85 (lH, s)
-
- (1) 1,5-Dichloro-2-pentanone (12.9 g) was obtained by reacting 4-chlorobutyryl chloride (16.5 g) with diazomethane in diethyl ether and hydrogen chloride according to a similar manner to that of Preparation 1-(1), bp 72-95°C/4-8 mmHg.
- (2) 2-Amino-4-(3-chloropropyl)thiazole (2.6 g) was obtained by reacting 1,5-dichloro-2-pentanone (3.1 g) with thiourea (1.52 g) according to a similar manner to that of Preparation 1-(2).
- (3) 2-Acetamido-4-(3-chloropropyl)thiazole (2.4 g) was obtained by reacting 2-amino-4-(3-chloropropyl)-thiazole (2.5 g) with acetyl chloride (1.1 ml) according to a similar manner to that of Preparation 1-(3), mp 110-112°C. IR cm-1 (Nujol) . 3200, 1645, 1555, 1300, 1000 NMR 6ppm (DMSO-d6) : 2.20 (2H, m), 2.25 (3H, s), 2.86 (2H, t, J=7.0Hz), 3.55 (2H, t, J=7.0Hz), 6.58 (lH, s), 9.0 (1H, s)
-
- (1) 2-Amino-5-(2-chloroethyl)-4-methylthiazole monohydrobromide (5.1 g) was obtained by reacting 3-bromo-5-chloro-2-pentanone (6.0 g) with thiourea (2.3 g) according to a similar manner to that of Preparation 1-(2).
- (2) 2-Acetamido-5-(2-chloroethyl)-4-methylthiazole (1.85 g) was obtained by reacting 2-amino-5-(2-chloroethyl)-4-methylthiazole monohydrobromide (2.8 g) with acetic anhydride (30 ml) according to a similar manner to that of Preparation 1-(3), mp 172-174°C. IR cm-1 (Nujol) : 3140, 1685, 1275, 718 NMR 6ppm (DMSO-d6) : 2.05 (3H, s), 2.15 (3H, s), 3.20 (2H, t, J=8.0Hz), 3.75 (2H, t, J=8.0Hz)
- 4-Chloromethyl-2-isopropylthiazole (5.5 g) was obtained by reacting thioisobutyramide (3.09 g) with 1,3-dichloro-2-propanone (3.81 g) in ethanol (50 ml) according to a similar manner to that of Preparation 1-(2).
-
- IR (Film) : 2960, 2925, 2860, 1610, 1480, 1460,
- 1265, 1155, 1060, 875, 730 cm-1
- 4-Chloromethyl-2-(N-methylacetamido)thiazole (3.1 g) was obtained by reacting 4-chloromethyl-2-(N-methylamino)thiazole monohydrochloride (5.6 g) with acetic anhydride (30 ml) according to a similar manner to that of Preparation 1-(3), mp 138-140°C.
-
- IR cm-1 (Nujol) : 1660, 1480, 1005, 715, 705
- NMR 6ppm (DMSO-d6) : 2.35 (3H, s), 3.78 (3H, s), 4.80 (2H, s), 7.30 (lH, s)
- A mixture of 2-acetamido-4-chloromethylthiazole (7.6 g), 1-benzhydrylpiperazine (10.0 g) and potassium carbonate (5.5 g) in N,N-dimethylformamide (80 ml) was stirred at 80°C for 2 hours. After the reaction mixture was poured into ice-water, the precipitated crystals were collected by filtration, washed with water and then recrystallized twice from methanol to give white crystals (8.4 g) of 2-acetamido-4-(4- benzhydrylpiperazin-1-ylmethyl)thiazole, mp 178-179°C.
-
- IR cm-1 (Nujol) : 3300, 3200, 1690, 1575, 1450, 1290, 705
- NMR δppm (DMSO-d6) : 2.10 (3H, s), 2.41 (8H, m), 3.52 (2H, s), 4.19 (lH, s), 6.93 (lH, s), 7.40 (10H, m), 10.40 (1H, s)
- Elemental Analysis: C23H26N40S
- 2-Acetamido-4-[4-(4-chlorobenzhydryl)piperazin-1-ylmethyl]thiazole (5.4 g) was obtained by reacting 2-acetamido-4-chloromethylthiazole (3.8 g) with 1-(4-chlorobenzhydryl)piperazine (5.7 g) according to a similar manner to that of Example 1, mp 140-145°C.
-
- IR cm-1 (Nujol) : 3300, 1695, 1545, 1000, 760
- NMR 6ppm (DMSO-d6) : 2.01 (3H, s), 2.3-2.5 (8H, m), 3.45 (2H, s), 4.22 (lH, s), 6.85 (1H, s), 7.05-7.30 (9H, m), 11.5 (lH, s)
- Elemental Analysis : C23H25ClN4OS
- A mixture of 2-acetamido-4-chloromethylthiazole (0.95 g), 1-benzhydrylperhydro-1,4-diazepine (1.33 g) and potassium carbonate (0.7 g) in N,N-dimethylformamide (5 ml) was stirred at 70°C for an hour. After the reaction mixture was poured into ice-water, it was extracted with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to give an amorphous product (1.7 g), which was chromatographed on silica gel (30 g) using a mixture of chloroform and methanol (20:1 by volume) as an eluent. The eluates containing the desired compound were collected and then evaporated to give an oil (1.4 g), which was dissolved in a mixture of methanol (10 ml) and conc. hydrochloric acid (5 ml), followed by refluxing for an hour. After removal of the methanol, the remained aqueous solution was neutralized with an aqueous solution of sodium bicarbonate. The precipitated crystals were collected by filtration, washed with water and then dried, followed by recrystallization from ethyl acetate to obtain pale yellow crystals (0.75 g) of 2-amino-4-(4- benzhydryl-perhydro-1,4-diazepin-1-ylmethyl)thiazole, mp 152-156°C.
-
- IR cm-1 (Nujol) : 3230, 1650, 1590, 1530, 710, 700
- NMR δppm (DMSO-d6) : 1.62 (2H, m), 2.3-2.5 (8H, m), 3.35 (2H, s), 4.64 (1H, s) , 6.15 (lH, s), 6.75 (2H, s), 7.0-7.45 (10H, m),
- Elemental Analysis : C22H26N4S
- A mixture of 2-acetamido-4-(2-chloroethyl)thiazole (4.56 g), 1-benzhydrylpiperazine (5.62 g) and potassium carbonate (3.08 g) in N,N-dimethylformamide (45 ml) was stirred at 65°C for 3.5 hours and at 100°C for additional 10 hours. After concentration of the reaction mixture, thereto was added ice-water, followed by extraction with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to give an amorphous product (10 g), which was chromatographed on silica gel (300 g) using a mixture of chloroform and methanol (20:1 by volume) as an eluent. The eluates containing the desired com- pound were collected and then evaporated to give an amorphous product,, which was transformed into its hydrochloride in a conventional manner, followed by recrystallization from a mixture of methanol and diethyl ether to obtain 2-acetamido-4-[2-(4- benzhydrylpiperazin-1-yl) ethyl]thiazoIe trihydrochloride (4.95 g), mp 182-190°C.
-
- IR cm 1 (Nujol) : 1660, 1550, 1290, 1005
- NMR δppm (DMSO-d6) : 2.24 (3H, s), 3.0-4.2 (12H, m), 6.1 (lH, broad), 7.06 (lH, s), 7.53 (5H, m), 8.10 (5H, m)
- Elemental Analysis : C24H28N4OS·3HCl·5/4 H20
- 2-Acetamido-4-[2-{4-(4-chlorobenzhydryl)piperazin-1-yl}ethyl]thiazole dihydrochloride (4.5 g) was obtained by reacting 2-acetamido-4-(2-chloroethyl)thiazole (6.0 g) with 1-(4-chlorobenzhydryl)piperazine (8.6 g) according to a similar manner to that of Example 4, mp 160-190°C.
-
- IR cm-1 (Nujol) : 3400, 2700-2350, 1695, 1550, 710
- NMR 6ppm (DMSO-d6) : 2.05 (3H, s), 3.1-3.7 (10H, broad), 5.55 (lH, broad), 6.90 (lH, s), 7.35-7.80 (9H, m)
- A mixture of 2-acetamido-4-(3-chloropropyl)thiazole (35.2 g), 1-benzhydrylpiperazine (40.8 g), potassium carbonate (22.3 g) and potassium iodide (1.0 g) in N,N-dimethylformamide (280 ml) was stirred at 70°C for 3 hours. After concentration of the reaction mixture, it was extracted with ethyl acetate, followed by removal of the insoluble substance by filtration. The filtrate was washed with water, dried over anhydrous magnesium sulfate and then evaporated to give an oil (55 g), which was chromatographed on silica gel (700 g) using a mixture of chloroform and methanol (100:1 by volume) as an eluent. The eluates containing the desired compound were collected and then evaporated to give an amorphous product (15.5 g), which was transformed into its fumarate in a conventional manner, followed by recrystallization from ethanol to obtain white crystals (11.2 g) of 2-acetamido-4-[3-(4- benzhydrylpiperazin-1-yl)propyl]thiazole hemifumarate, mp 213-215°C.
-
- IR cm-1 (Nujol) : 3150, 3100, 1690, 1540, 750, 710
- NMR 6ppm (DMSO-d6) : 1.80 (2H, m), 2.09 (3H, s), 2.2-2.6 (12H, broad), 4.26 (1H, s), 6.05 (2H, broad), 6.53 (lH, s), 6.66 (lH, s), 7.05-7.55 (10H, m)
- Elemental Analysis : C25H30N4OS·1/2 C 4 H 4 0 4
- A mixture of 4-chloromethyl-2-methylthiazole hydrochloride (1.84 g), 1-benzhydrylpiperazine (2.52 g) and potassium carbonate (2.7 g) in N,N-dimethylformamide (15 ml) was stirred at 70°C for an hour. After the reaction mixture was poured into ice-water, it was extracted with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to give a residue, which was transformed into its hydrochloride in a conventional manner, followed by recrystallization from a mixture of methanol and diethyl ether to obtain white crystals (2.0 g) of 4-(4-benzhydrylpiperazin-1-ylmethyl)-2-methylthiazole trihydrochloride, mp 166-170°C (dec.).
-
- IR cm-1 (Nujol) : 2800-2400, 1600, 1500, 705
- NMR δppm (DMSO-d6) : 2.78 (3H, s), 3.6-3.8 (8H, broad), 4.62 (2H, s), 6.15 (lH, s), 7.50 (7H, m), 8.05 (7H, m),
- Elemental Analysis : C22H25N3S·3HCl·1/2H2O
- 4-[4-(4-Chlorobenzhydryl)piperazin-I-ylmethyl]-2-methylthiazole monofumarate (2.6 g) was obtained by reacting 4-chloromethyl-2-methylthiazole monohydrochloride (1.84 g) with 1-(4-chlorobenzhydryl)piperazine (2.86 g) according to a similar manner to that of Example 7, mp 195-197°C.
-
- IR cm-1 (Nujol) : 2600, 1710, 1635, 1580, 1200, 760
- NMR 6ppm (DMSO-d6) : 2.4-2.55 (8H, m), 2.65 (3H, s), 3.75 (2H, s), 4.25 (lH, s), 6.65 (2H, s), 7.2-7.5 (10H, m), 9.91 (2H, broad)
- Elemental Analysis : C22H24ClN3S·C4H4O4
- A mixture of 4-chloromethyl-2-methylaminothiazole monohydrochloride (2.2 g), 1-benzhydrylpiperazine (2.5 g) and potassium carbonate (2.7 g) in N,N-dimethylformamide (15 ml) was stirred at 70°C for an hour. After the reaction mixture was poured into ice-water, it was extracted with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to dryness to give an oil, which was transformed into its hydrochloride in a conventional manner, followed by recrystallization from a mixture of methanol and diethyl ether to obtain white crystals (1.2 g) of 4-(4-benzhydrylpiperazin-l-ylmethyl)-2-methylaminothiazole trihydrochloride, mp 225-228°C (dec.).
-
- IR cm-1 (Nujol) : 3450, 3170, 2800-2400, 1625, 1500, 710
- NMR 6ppm (DMSO-d6) : 3.00 (3H, s), 3.4-3.7 (8H, broad), 4.35 (2H, s), 5.75 (lH, s), 7.20 (1H, s), 7.45-7.8 (10H, m), 8.6 (5H, broad)
- A mixture of 4-chloromethyl-2-(N-methylacetamido)-thiazole (2.05 g), 1-benzhydrylpiperazine (2.5 g) and potassium carbonate (1.4 g) in N,N-dimethylformamide (20 ml) was stirred at 80°C for 1.5 hours. After the reaction mixture was poured into ice-water, the precipitated crystals were washed with water and then dried, followed by recrystallization from a mixture of ethyl acetate and n-hexane to obtain pale yellow crystals of 4-(4-benzhydrylpiperazin-1-ylmethyl)-2-(N-methylacetamido)thiazole (1.3 g), mp 140-142°C.
-
- IR cm-1 (Nujol) : 1655, 1490, 1000, 760, 705
- NMR 6ppm (DMSO-d6) : 2.25 (3H, s), 2.3-2.55 (8H, m), 3.52 (2H, s), 3.60 (3H, s), 4.25 (lH, s), 6.90 (lH, s), 7.1-7.5 (10H,m)
- Elemental Analysis : C24H28N4OS
-
- (1) A solution of 1-bromo-5-chloro-2-pentanone (6.7 g) and thioacetamide (2.5 g) in methanol (10 ml) was stirred at 50°C for 5 hours. After concentration of the reaction mixture, the residue was allowed to stand for 10 days. The crystalline residue was suspended in a mixture of methanol and diethyl ether and the remained solid was collected by filtration to give brown powder (7.3 g) of 4-(3-chloropropyl)-2-methylthiazole monohydrobromide.
- (2) A mixture of the above object compound (2.6 g), 1-benzhydrylpiperazine (2.5 g) and potassium carbonate (2.75 g) in N,N-dimethylformamide (20 ml) was stirred at 70°C for 2 hours. After concentration of the reaction mixture, the concentrate was extracted with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to give an oily residue (4.4 g), which was chromatographed on silica gel (80 g) using a mixture of ethyl acetate and methanol (50: 1 by volume) as an eluent. The eluates containing the desired compound were collected and evaporated to dryness under reduced pressure to give an oil (1.25 g), which was transformed into its fumarate in a conventional manner, followed by recrystallization from a mixture of ethanol and diethyl ether to obtain white crystals (0.5 g) of 4-[3-(4-benzhydrylpiperazin-l-yl)propyl]-2-methylthiazole monofumarate, mp 183-185°C.
-
- IR cm-1 (Nujol) : 2500-2300, 1690, 1635, 1580, 1200, 760, 710
- NMR δppm (DMSO-d6) : 1.86 (2H, m), 2.45-2.85 (15H, m), 4.31 (lH, s), 6.61 (2H, s), 7.08 (lH, s), 7.15-7.55 (10H, m), 8.2 (2H, broad)
- Elemental Analysis : C24H29N3S·C4H4O4
- A mixture of 4-chloromethylthiazole monohydrochloride (1.7 g), 1-benzhydrylpiperazine (3.21 g) and potassium carbonate (5.3 g) in N,N-dimethylformamide (40 ml) was stirred at 65°C for 2 hours. After concentration of the reaction mixture, the concentrate was extracted with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to dryness to give a residue, which was chromatographed on silica gel (120 g) using a mixture of chloroform and methanol (50:1 by volume) as an eluent. The eluates containing the desired compound were collected and evaporated to dryness under reduced pressure to give crystals, which were recrystallized from chloroform to obtain white crystals (1.2 g) of 4-(4-benzhydrylpiperazin-1-ylmethyl)-thiazole, mp 114-116°C.
-
- IR cm-1 (Nujol) : 1450, 1310, 1155, 1010, 850, 710
- NMR 6ppm (DMSO-d6) : 2.5 (8H, m), 3.70 (2H, s), 4.20 (lH, s), 7.05-7.50 (11H, m), 8.60 (lH, d, J=3.0Hz) Elemental Analysis : C21H23N3S
- A mixture of 2-acetamido-5-(2-chloroethyl)-4-methylthiazole (1.8 g), 1-benzhydrylpiperazine (2.07 g) and potassium carbonate (1.13 g) in N,N-dimethylformamide (20 ml) was stirred at 80°C for 2.5 hours. After the reaction mixture was poured into ice-water, it was extracted with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to give an amorphous product (3 g), which was chromatographed on silica gel (30 g) using ethyl acetate as an eluent. The eluates containing the desired compound were collected and evaporated to dryness to give crystals (1.4 g), which were recrystallized from a mixture of ethyl acetate and diethyl ether to obtain white crystals (0.6 g) of 2-acetamido-5-[2-(4- benzhydrylpiperazin-1-yl)ethyl]-4-methylthiazole, mp 166-168°C.
-
- IR cm-1 (Nujol) : 3180, 1695, 1560, 715
- NMR 6ppm (DMSO-d6) : 2.06 (3H, s), 2.11 (3H, s), 2.20-2.80 (12H, m), 4.24 (lH, s), 7.2-7.6 (10H, m), 13.18 (lH, s)
- Elemental Analysis : C25H30N4OS
- A mixture of 2-acetamido-5-chloro-4-chloromethylthiazole (450 mg), 1-benzhydrylpiperazine (504 mg) and potassium carbonate (276 mg) in N,N-dimethylformamide (3 ml) was stirred at 70°C for 20 minutes. After the reaction mixture was poured into ice-water, the precipitated crystals were collected by filtration, washed with water and then dried, followed by recrystallization from a mixture of ethyl acetate and n-hexane to obtain crystals (355 mg) of 2-acetamido-5-chloro-4-(4-benzhydrylpiperazin-l-ylmethyl)thiazole, mp 227-230°C.
-
- IR cm-1 (Nujol) : 3200, 1655, 1550, 760, 705
- NMR 6ppm (DMSO-d6) : 2.10 (3H, s), 2.30 (8H, m), 3.55 (2H, s), 4.21 (lH, s), 7.4-7.6 (10H, m), 14.10 (lH, s)
- Elemental Analysis : C23H25ClN4OS
- A mixture of 4-chloromethyl-2-phenylthiazole monohydrochloride (2.46 g), 1-benzhydrylpiperazine (2.52 g) and potassium carbonate (1.4 g) in N,N-dimethylformamide (40 ml) was stirred at 70°C for 2 hours. After the reaction mixture was poured into ice-water, it was extracted with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to give an oil of 4-(4-benzhydrylpiperazin-1-ylmethyl)-2-phenylthiazole, which was transformed into its hydrochloride in a conventional manner, followed by recrystallization from ethanol to obtain white crystals (2.7 g) of 4-(4-benzhydrylpiperazin-1-ylmethyl)-2-phenylthiazole dihydrochloride, mp 215-218°C.
-
- IR cm-1 (Nujol) : 3400, 1460, 1035, 780, 710
- NMR (DMSO-d6) . 3.1-4.0 (8H, m), 4.58 (2H, s), 5.70 (1H, broad), 7.1-7.6 (10H, m), 7.6-8.1 (8H, m)
- Elemental Analysis : C27H 27N3S·2HCl·1/4H2O
-
- (1.) Hydrogen sulfide was introduced into a mixture of dimethylcyanamide (8.75 g), triethylamine (12.6 g) and pyridine (17.5 ml) at 60°C for 2 hours. After addition of petroleum ether (25 ml), the solution was ice-cooled. The precipitated crystals were collected by filtration, washed with petroleum ether and then dried, followed by recrystallization from water to give crystals (7.6 g) of N,N-dimethylthiourea, mp 160-160.5°C.
- (2) A mixture of the above object compound (3.1 g), l,3-dichloro-2-propanone (3.8 g) in methanol (150 ml) was stirred at ambient temperature for 4 hours. After concentration of the reaction mixture, the residue was extracted with ethyl acetate, followed by neutralization with an aqueous solution of sodium bicarbonate and washing with an aqueous solution of sodium chloride. After drying over anhydrous magnesium sulfate, the solvent was removed by evaporation to obtain 4-chloromethyl-2-dimethylaminothiazole (5.3 g).
- (3) A mixture of 4-chloromethyl-2-dimethylamino- thiazole (2.62 g), 1-benzhydrylpiperazine (3.74 g) and potassium carbonate (2.07 g) in N,N-dimethylformamide (30 ml) was stirred at 60°C for 5 hours. After the reaction mixture was poured into ice-water, it was extracted with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to dryness to give an oily residue, which was chromatographed on silica gel (120 g) using a mixture of chloroform and methanol (97:3 by volume) as an eluent. The eluates containing the desired compound were collected and evaporated to give a brown oil (3.4 g), which was transformed into its fumarate in a conventional manner, followed by recrystallization from a mixture of ethanol and diethyl ether to obtain pale-yellow crystals (1.52 g) of 4-(4-benzhydrylpipe-razin-1-ylmethyl)-2-dimethylaminothiazole monofumarate, mp 180-183.5°C.
-
- IR cm-1 (Nujol) : 1706, 1635, 1560, 1238, 1196, 966, 705
- NMR δppm (DMSO-d6) : 2.40 (4H, m), 2.66 (4H, m), 3.56 (2H, s), 4.32 (1H, s), 6.54 (lH, s), 6.62 (2H, s), 7.0-7.5 (10H, m), 10.22 (2H, broad s)
- Elemental Analysis : C23H28N4S·C4H4O4
- A mixture of 4-chloromethyl-2-isopropylthiazole (3.51 g), 1-benzhydrylpiperazine (5.04 g) and potassium carbonate (1.52 g) in N,N-dimethylformamide (60 ml) was stirred at 60°C for 2 hours. After the reaction mixture was poured into ice-water, it was extracted twice with ethyl acetate. The combined extracts were washed with water, dried over anhydrous magnesium sulfate and then evaporated to give an oil (9.5 g), which was chromatographed on silica gel (150 g) using chloroform and a mixture of chloroform and methanol (50:1 by volume) as an eluent. The eluates containing the desired compound were collected and evaporated to give a brown oil (6.9 g), which was transformed into its fumarate in a conventional manner, followed by recrystallization from ethanol to obtain white crystals (4.6 g) of 4-(4-benzhydrylpiperazin-I-ylmethyl)-2-isopropylthiazole monofumarate, mp 202-203.5°C.
-
- IR cm-1 (Nujol) : 1700, 1640, 1580, 1450, 1365, 1250, 1195, 980, 760, 705
- NMR 6ppm (DMSO-d6) : 1.25 (6H, d, J=7Hz), 2.1-2.75 (8H, m), 3.20 (lH, septet), 3.63 (2H, s), 4.25 (lH, s), 6.59 (lH, s), 7.05-7.55 (10H, m), 10.22 (2H, broad)
- Elemental Analysis : C24H29N3S·C4H4O4
- To a solution of 2-amino-4-chloromethylthiazole monohydrochloride (1.85 g) in N,N-dimethylformamide (7 ml) and pyridine (2 ml) was added dropwise methanesulfonyl chloride (0.85 ml) with stirring, and the stirring was continued at ambient temperature for half an hour. After concentration of the reaction mixture, the concentrate was neutralized with an aqueous solution of sodium bicarbonate, followed by extraction with ethyl acetate. The extract was washed with water, dried and then evaporated to give a brown oil (1.4 g). A mixture of this oil, 1- benzhydrylpiperazine (1.5 g) and potassium carbonate (0.85 g) in N,N-dimethylformamide (10 ml) was stirred at 80°C for 1.5 hours. After the reaction mixture was poured into ice-water, it was extracted with water, dried over anhydrous magnesium sulfate. Removal of the solvent gave an oil (2.0 g), which was chromatographed on silica gel (40 g) using a mixture of chloroform and methanol (10:1 by volume) as an eluent. The eluates containing the desired compound were collected and evaporated to give crystals, which were recrystallized from ethyl acetate to obtain yellow crystals (0.5 g) of 4-(4-benzhydrylpiperazin-l-ylmethyl)-2-[N-(N,N-dimethylamino)methyleneamino]-thiazole, mp 148-150°C.
-
- IR cm-1 (Nujol) : 1610, 1450, 1090, 1010, 755, 715
- NMR 6ppm (DMSO-d6) : 2.4-2.6 (8H, m), 2.86 (3H, s), 3.00 (3H, s), 3.33 (2H, s), 4.21 (lH, s), 6.63 (1H,s), 7.05-7.50 (10H, m), 8.16 (1H, s)
- Elemental Analysis : C24H29N5S
- A mixture of 2-acetamido-4-(4-benzhydryl- piperazin-1-ylmethyl)thiazole (4.6 g), methanol (80 ml) and conc. hydrochloric acid (20 ml) was refluxed under heating for 3 hours with stirring. After concentration of the reaction mixture, the concentrate was neutralized with an aqueous solution of sodium bicarbonate, followed by extraction with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to give an amorphous product (4.0 g), which was chromatographed on silica gel using a mixture of ethyl acetate and methanol (10:1 by volume) as an eluent. The eluates containing the desired compound were collected and evaporated to give crystals, which were recrystallized from a mixture of ethyl acetate and diethyl ether to obtain white crystals (2.6 g) of 2-amino-4-(4- benzhydrylpiperazin-1-ylmethyl)thiazole, mp 156-160°C.
-
- IR cm-1 (Nujol) : 3400, 3250, 1600, 1515, 1020, 760
- NMR 6ppm (DMSO-d6) : 2.41 (8H, m), 3.30 (2H, s), 4.32 (lH, s), 6.25 (lH, s), 6.80 (2H, s), 7.30 (10H, m)
- Elemental Analysis : C21H24N4S
- 2-Amino-4-[4-(4-chlorobenzhydryl)piperazin-l-ylmethyl]thiazole (4.1 g) was obtained by hydrolyzing 2-acetamido-4-[4-(4-chlorobenzhydryl)piperazin-l-ylmethyl]thiazole (6.0 g) with conc.hydrochloric acid (10 ml) according to a similar manner to that of Example 19.
-
- IR cm-1 (Nujol) : 3230, 3100, 1640, 1535, 1135
- NMR δppm (DMSO-d6) : 2.3-2.6 (8H, m), 3.32 (2H, s), 4.23 (1H, s), 6.21 (lH, s), 6.85 (2H, s), 7.1-7.4 (9H, m)
- Elemental Analysis : C21H23ClN4S
- A mixture of 2-acetamido-4-[2-(4-benzhydryl- piperazin-1-yl)ethyl]thiazole (3.75 g), methanol (26 ml) and conc. hydrochloric acid (13 ml) was refluxed under heating for 2.5 hours. After concentration of the reaction mixture, the concentrate was recrystallized from methanol to obtain white crystals (3.4 g) of 2-amino-4-[2-(4-benzhydxylpiperazin-1-y1)ethyl]-thiazole trihydrochloride, mp 188-190°C.
-
- IR cm-1 (Nujol) : 1645, 1460, 1380, 920, 710
- NMR σppm (DMSO-d6) : 2.9-3.9 (14H, m), 5.8 (1H, broad), 6.78 (1H, s), 7.2-7.6 (6H, m), 7.8-8.1 (4H, m), 8.2-10.1 (3H, broad)
- Elemental Analysis : C22H26N4S·3HCl.1/2H2O
- 2-Amino-4-[2-14-(4-chlorobenzhydryl)piperazin-1-yl}ethyl]thiazole trihydrochloride (2.65 g) was obtained by hydrolyzing 2-acetamido-4-[2-{4-(4-chlorobenzhydryl)piperazin-1-yl}ethyl]thiazole (5.0 g) with conc. hydrochloric acid (10 ml) according to a similar manner to that of Example 21, mp 180-185°C (dec.).
-
- IR cm-1 (Nujol) : 3210, 3050, 2700-2300, 1640, 1605, 765, 725
- NMR δppm (DMSO-d6) : 3.2-3.7 (I2H, broad), 5.81 (1H, broad), 6.85 (lH, s), 7.4-7.9 (9H, m), 9.20 (5H, broad)
- Elemental Analysis : C22H25ClN4S·3HCl.1/4H2O
- A mixture of 2-acetamido-4-[3-(4-benzhydryl- piperazin-1-yl)propyl]thiazole (1.2 g), methanol (25 ml) and conc. hydrochloric acid (6 ml) was refluxed under heating for 5 hours. After concentration of the reaction mixture, the resultant crystals were recrystallized from a mixture of methanol and diethyl ether to obtain white crystals (1.05 g) of 2-amino-4-[3-(4-benzhydrylpiperazin-1-yl)propyl]-thiazole trihydrochloride, mp 205-215°C.
-
- IR cm-1 (Nujol) : 3400, 3200, 2800-2400, 1620, 1580
- NMR δppm (DMSO-d6) 2.10 (2H, broad), 2.62 (2H, broad), 3.30 (6H, broad), 3.75 (4H, broad), 5.80 (lH, broad), 6.74 (lH, s), 7.45 (10H, m), 7.95 (5H, broad) Elemental Analysis : C23H28N4S·3HCl·H2O
- A mixture of 2-acetamido-4-(4-benzhydrylpiperazin-1-ylmethyl)-5-chlorothiazole (5.4 g), methanol (50 ml) and conc, hydrochloric acid (12.5 ml) was refluxed under heating for 6 hours. After concentration of the reaction mixture, the resultant crystals were recrystallized from methanol to obtain white crystals (1.3 g) of 2-amino-4-(4-benzhydrylpiperazin-1-ylmethyl)-5-chlorothiazole trihydrochloride, mp 210-250°C.
-
- IR cm-1 (Nujol) : 3600, 3450, 2800-2400, 1640, 1580
- NMR δppm (DMSO-d6) : 3.5-3.7 (8H, m), 4.20 (2H, s), 5.95 (lH, broad), 7.0-7.4 (3H, broad), 7.40-7.95 (10H, m)
- Elemental Analysis : C21H23ClN4S·3HCl
- To a solution of 2-amino-4-(4-benzhydryl- piperazin-1-ylmethyl)thiazole (1.82 g) and triethylamine (1.4 ml) in chloroform (18 ml) was added dropwise methanesulfonyl chloride (0.78 ml) under ice-cooling with stirring, and the stirring was continued at the same temperature for 1.25 hours. After concentration of the reaction mixture, the residue was neutralized with an aqueous solution of sodium bicarbonate, followed by extraction with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to give an amorphous product (2.2 g), which was chromatographed on silica gel (40 g) using a mixture of chloroform and methanol (50:1 by volume) as an eluent. The eluates containing the desired compound were collected and then evaporated to give crystals, which were recrystallized from ethyl acetate to give white crystals (0.65 g) of 4-(4-benzhydrylpiperazin-l-ylmethyl)-2-methanesulfon- amidothiazole, mp 177-179°C.
-
- IR cm-1 (Nujol) : 3170, 1610, 1530, 1445, 1265, 1125, 770, 700
- NMR δppm (DMSO-d6) : 2.4-2.8 (8H, m), 2.91 (3H, s), 3.43 (2H, s), 4.38 (lH, s), 6.71 (lH, s), 7.2-7.8 (10H, m), 9.50 (lH, broad)
- Elemental Analysis : C22H26N4O2S2
- The eluates obtained from the other part was evaporated to dryness to give a residue, which was recrystallized from a mixture of chloroform and diethyl ether to obtain 4-(4-benzhydrylpiperazin-1-ylmethyl)-2-(N,N-dimesylamino)thiazole (0.47 g), mp 167- 168°c.
-
- IR cm-1 (Nujol) : 1600, 1595, 1370, 1160, 760, 710
- NMR δppm (DMSO-d6) : 2.15-2.55 (8H, broad), 3.56 (8H, s), 4.39 (1H, s), 7.05-7.5 (10H, m), 7.59 (1H, s)
- Elemental Analysis : C23H28N4O4S3
- To a solution of 2-amino-4-(4-benzhydrylpiperazin-1-ylmethyl)thiazole (1.8 g) and triethylamine (1.4 ml) in chloroform (15 ml) was added dropwise ethanesulfonyl chloride (1.28 g) under ice-cooling with stirring, and the stirring was continued at the same temperature for 45 minutes and at ambient temperature for additional 2.5 hours. After concentration of the reaction mixture, the residue was neutralized with an aqueous solution of sodium bicarbonate, followed by extraction with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to give an oil (3 g), which was chromatographed on silica gel (90 g) using a mixture of chloroform and methanol (50:1 by volume) as an eluent. The eluates containing the desired compound were collected and then evaporated to give an amorphous product, which was recrystallized from ethyl acetate to give crystals (1.2 g) of 4-(4-benzhydrylpiperazin-1-ylmethyl)-2-ethanesulfonamidothiazole, mp 159-160.5°C.
-
- IR cm-1 (NujoT) : 3080, 1612, 1558, 1448, 1318, 1300, 1135
- NMR δppm (DMSO-d6) : 1.15 (3H, t, J=7.0Hz), 2.1-2.6 (8H, m), 2.94 (2H, q, J=7.0Hz), 3.32 (2H, s), 4.26 (1H, s), 6.47 (lH, s), 7.0-7.6 (10H, m), 8.0-9.5 (lH, broad) Elemental Analysis : C23H28N4O2S2
- To a solution of 2-amino-4-(4-benzhydrylpiperazin- l-ylmethyl)thiazole (1.8 g) and triethylamine (1.4 ml) in chloroform (15 ml) was added dropwise propanesulfonyl chloride (1.42 g) under ice-cooling with stirring, and the stirring was continued at the same temperature for 70 minutes. After concentration of the reaction mixture, the residue was neutralized with an aqueous solution of sodium bicarbonate, followed by extraction with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to give an oil (2.9 g), which was chromatographed on silica gel (30 g) using a mixture of chloroform and methanol (50:1 by volume) as an eluent. The eluates containing the desired compound were collected and then evaporated to give a foamy product, which was recrystallized from ethyl acetate to give white crystals (0.9 g) of 4-(4-benzhydrylpiperazin-1-ylmethyl)-2-propanesulfon- amidothiazole, mp 165-167°C.
-
- IR cm-1 (Nujol) : 3220, 1540, 1275, 1220, 1000, 887, 708
- NMR 6ppm (DMSO-d6) : 0.95 (3H, t, J=7.0Hz), 1.68 (2H, m), 2.1-2.8 (8H, m), 2.98 (2H, t, J=7.0Hz), 3.36 (2H, s), 4.31 (lH, s), 6.53 (lH, s), 7.1-7.8 (10H, m), 7.8-8.0 (lH, broad) Elemental Analysis : C24H30N4O2S2
- 4-(4-Benzhydrylpiperazin-1-ylmethyl)-2-n-butanesulfonamidothiazole (1.8 g) was obtained by reacting 2-amino-4-(4-benzhydrylpiperazin-1-ylmethyl)-thiazole (2.73 g) with n-butanesulfonyl chloride (2.35 g) according to a similar manner to that of Example 27, mp 185-187°C.
-
- IR cm-1 (Nujol) : 3200, 1524, 1260, 1118, 1030, 880, 708
- NMR 6ppm (DMSO-d6) : 0.83 (3H, m), 1.0-2.0 (4H, m), 2.37 (8H, m), 2.75-3.2 (2H, m), 3.33 (2H, s), 4.26 (lH, s), 6.49 (1H, s), 7.1-7.55 (10H, m), 8.0-11:0 (1H, broad s)
- Elemental Analysis C25H32N4O2S2
- To a solution of 2-amino-4-(4-benzhydrylpiperazin-l-ylmethyl)thiazole ( 1.1 g) in tetrahydrofuran (10 ml) and pyridine (5 ml) was added dropwise propionyl chloride (0.92 ml) under ice-cooling with stirring, and the stirring was continued at the same temperature for an hour. After concentration of the reaction mixture the residue was extracted with ethyl acetate, followed by washing with an aqueous solution of sodium bicarbonate and water and drying over anhydrous magnesium sulfate. Removal of the solvent gave an oil, which was transformed into its hydrochloride in a conventional manner, followed by recrystallization from a mixture of methanol and diethyl ether to obtain white crystals (0.8 g) of 4-(4-benzhydrylpiperazin-l-ylmethyl)-2-propionamidothiazole dihydrochloride, mp 181-184°C (dec.).
-
- IR cm-1 (Nujol) : 3380, 2400, 1680, 1540, 710
- NMR 6ppm (DMSO-d6) : 1.05 (3H, t), 2.51 (2H, q, ) 3.18 (4H, broad), 3.61 (4H, broad), 4.46 (2H, s), 5.58 (lH, broad), 7.5-7.8 (12H, m), 13.05 (lH, s)
- Elemental Analysis : C24H28N4OS·2HCl
- 4-(4-Benzhydrylpiperazin-1-ylmethyl)-2- butyramidothiazole (0.55 g) was obtained by reacting 2-amino-4-(4-benzhydrylpiperazin-1-ylmethyl)thiazole (1.1 g) with butyryl chloride (0.93 ml) according to a similar manner to that of Example 29, mp 128-135°C.
-
- IR cm-1 (Nujol) : 3180, 1695, 1570, 1560, 705
- NMR δppm (DMSO-d6) : 0.9 (3H, t), 1.61 (2H, m), 2.43 (10H, m), 3.49 (2H, s), 4.18 (lH, s), 6.85 (lH, s), 7.10 (10H, m), 11.95 (lH, s)
- Elemental Analysis : C25H30N4OS
- 4-(4-Benzhydrylpiperazin-1-ylmethyl)-2-isobutyramidothiazole (0.4 g) was obtained by reacting 2-amino-4-(4-benzhydrylpiperazin-1-ylmethyl)thiazole (1.1 g) with isobutyryl chloride (0.8 g) acccrding to a similar manner to that of Example 29, mp 132-140°C.
-
- IR cm-1 (Nujol) : 3170, 1695, 1560, 1105, 710
- NMR δppm (DMSO-d6) : 1.05 (3H, s), 1.20 (3H, s) 2.4-2.5 (9H, m), 3.50 (2H, s), 4.15 (1H, s), 6.94 (lH, s), 7.33 (10H, m), 12.8 (lH, s)
- Elemental Analysis : C25H30N4OS
- 2-Benzamido-4-(4-benzhydrylpiperazin-1-ylmethyl)-thiazole dihydrochloride (1.1 g) was obtained by reacting 2-amino-4-(4-benzhydrylpiperazin-1-ylmethyl)-thiazole (1.8 g) with benzoyl chloride (1.4 ml) accord. ing to a similar manner to that of Example 29, mp 195-200°C (dec.).
-
- IR cm-1 (Nujol) : 3300, 2500-2400, 1655, 1550, 710
- NMR 6ppm (DMSO-d6) : 3.25 (4H, broad), 3.70 (4H, broad), 4.45 (2H, s), 5.60 (lH, broad), 7.3-8.0 (18H, m)
- 2-(p-Anisoylamino)-4-(4-benzhydrylpiperazin-l-ylmethyl)thiazole dihydrochloride (0.65 g) was obtained by reacting 2-amino-4-(4-benzhydrylpiperazin-l-ylmethyl)thiazole (1.1 g) with p-anisoyl chloride (1.3 g) according to a similar manner to that of Example 29, mp 175-190°C.
-
- IR cm-1 (Nujol) : 3400, 2500, 1660, 1600, 710
- NMR 6ppm (DMSO-d6) : 3.25 (4H, broad), 3.65 (4H, broad), 3.93 (3H, s), 4.45 (2H, s), 5.51 (lH, broad), 7.8-8.0 (16H, m), 13.4 (lH, s)
- 4-(4-Benzhydrylpiperazin-1-ylmethyl)-2-cyclo- hexylcarboxamidothiazole dihydrochloride (0.8 g) was obtained by reacting 2-amino-4-(4-benzhydrylpiperazin- l-ylmethyl)thiazole (1.1 g) with cyclohexylcarbonyl chloride (1.68 ml) according to a similar manner to that of Example 29, mp 200-207°C.
-
- IR cm-1 (Nujol) : 3450, 3100, 2400, 1670, 1550, 710
- NMR δppm (DMSO-d6) : 1.2-1.9 (10H, broad), 3.2-3.6 (8H, broad), 4.35 (2H, s), 5.51 (lH, broad), 7.4-7.8 (12H, m), 12.10 (1H, s)
- Elemental Analysis : C28H34N4OS·2HCl·1/2H2O
- The solution of 2-amino-4-(4-benzhydrylpiperazin- l-ylmethyl)thiazole (1.1 g) and methyl isocyanate (0.54 ml) in chloroform (10 ml) was refluxed for 2 hours. After concentration of the reaction mixture, the residue was extracted with ethyl acetate, followed by washing with an aqueous solution of sodium bicarbonate and water, drying over anhydrous magnesium sulfate and then evaporating to dryness to give an amorphous product (1.4 g), which was chromatographed on silica gel (about 30 g) using a mixture of chloroform and methanol (50:1 by volume) as an eluent. The eluates containing the desired compound were collected and evaporated to give a residue, which was transformed into its fumarate in a conventional manner, followed by recrystallization from a mixture of ethanol and diethyl ether to obtain white crystals (0.38 g) of 4-(4-benzhydrylpiperazin-l-ylmethyl)-2-(3-methylureido)thiazole monofumarate, mp 188-191°C.
-
- IR cm-1 (Nujol) : 3440, 3300, 2400, 1675, 1635, 1565, 760, 705
- NMR δppm (DMSO-d6) : 2.5-2.7 (11H, m), 3.56 (2H, s), 4.33 (lH, s), 6.50-7.00 (2H, broad), 6.66 (2H, s), 6.79 (lH,s), 7.1-7.7 (10H, m)
- Elemental Analysis : C23H27N5OS·C4H4O4·4/5H2O
- To a solution of 2-amino-4-(4-benzhydrylpiperazin- l-ylmethyl)thiazole (1.8 g) in tetrahydrofuran (5 ml) and pyridine (10 ml) was added dropwise ethoxalyl chloride (1.1 g) under ice-cooling with stirring, and the stirring was continued at the same temperature for an hour. After concentration of the reaction mixture, the residue was extracted with ethyl acetate, washed with water, dried over anhydrous magnesium sulfate and then evaporated to dryness to give a residue, which was chromatographed on silica gel using ethyl acetate as an eluent. The eluates containing the desired compound were collected and evaporated, followed by recrystallization from a mixture of ethyl acetate and n-hexane to obtain pale yellow crystals (0.7 g) of 4-(4-benzhydrylpiperazin-1-ylmethyl)-2-ethoxalyl- aminothiazole, mp 125-128°C.
-
- IR cm-1 (Nujol) : 3150, 1745, 1700, 1550, 760
- NMR 6ppm (DMSO-d6) : 1.31 (3H, t, 2.60 (8H, m), 3.61 (2H, s), 4.25 (lH, s), 4.30 (2H, q), 7.10 (lH, s), 7.3-7.6 (10H, m)
- Elemental Analysis : C25H28N4O3S
- To a solution of 2-amino-4-[2-(4-benzhydryl- piperazin-1-yl)ethyl]thiazole (1.7 g) and triethylamine (1.26 ml) in chloroform (17 ml) was added dropwise methanesulfonyl chloride (1028 mg) under cooling with stirring, and the stirring was continued at the same temperature for 2.7 hours. After concentration of the reaction mixture, the residue was neutralized with an aqueous solution of sodium bicarbonate, followed by extraction with ethyl acetate.
- The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to give an amorphous product (2.5 g), which was chromatographed on silica gel (60 g) using a mixture of chloroform and methanol (50:1 by volume) as an eluent. The eluates containing a desired compound were collected and evaporated to give an oil, which was transformed into its hydrochloride in a conventional manner, followed by recrystallization from methanol to obtain white crystals (1.2 g) of 4-[2-(4-benzhydrylpiperazin-1-yl)-ethyl]-2-methanesulfonamidothiazole dihydrochloride, mp 190-205°C.
-
- IR cm-1 (Nujol) : 3400, 2400, 1605, 1520, 1300, 1130, 705
- NMR δppm (DMSO-d6) : 2.85 (3H, s), 3.0-3.75 (12H, m), 5.50 (1H, broad), 6.53 (1H, s), 7.2-7.9 (10H, m)
- Elemental Analysis : C23H28N4O2S2·2HCl·1/2H2O
- To a solution of 2-amino-4-[3-(4- benzhydrylpiperazin-1-yl)propyl]thiazole (0.9 g) and triethylamine (0.64 ml) in chloroform (9 ml) was added dropwise methanesulfonyl chloride (520 mg) under cooling with stirring, and the stirring was continued at the same temperature for 2 hours and then at ambient temperature overnight. After concentration of the reaction mixture, the residue was neutralized with an aqueous solution of sodium bicarbonate, followed by extraction with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to give an oil (1.3 g), which was chromatographed on silica gel (30 g) using a mixture of chloroform and methanol (50:1 by volume) as an eluent. The eluates containing a desired compound were collected and evaporated to give crystals (0.75 g), which were recrystallized from ethyl acetate to give yellow crystals (0.41 g) of 4-[3-(4-benzhydrylpiperazin-1-yl)propyl]-2- methanesulfonamidothiazole, mp 181-183°C.
-
- IR cm-1 (Nujol) : 3550, 1540, 1460, 1275, 1120, 760, 705
- NMR δppm (DMSO-d6) : 1.73 (2H, m), 2.25-2.70 (12H, m), 2.86 (3H, s), 4.32 (lH, s), 5.30 (lH, broad), 6.36 (lH, s), 7.2-7.6 (10H, m)
- Elemental Analysis : C24H30N4O2S2
- 4-[3-(4-Benzhydrylpiperazin-1-yl)propyl]-2-ethanesulfonamidothiazole (0.9 g) was obtained by reacting 2-amino-4-[3-(4-benzhydrylpiperazin-1-yl)-propyl]thiazole (2.0 g) with ethanesulfonyl chloride (1.28 g) according to a similar manner to that of Example 38, mp 162-164°C.
-
- IR cm-1 (Nujol) : 1460, 1370, 1290, 1263, 1115, 985, 747, 720
- NMR 6ppm (DMSO-d6) : 1.17 (3H,t, J=8.0Hz), 1.4-2.7 (14H, m), 2.97 (2H, q, J=8.0Hz), 4.30 (lH, s), 6.34 (1H, s), 7.1-7.6 (10H, m)
- Elemental Analysis : E25H32N4O2S2
- To a solution of 2-amino-4-(4-benzhydrylpiperazin-1-ylmethyl)-5-chlorothiazole (3.2 g) in tetrahydrofuran (20 ml) and pyridine (10 ml) was added dropwise ethoxalyl chloride (2.2 g) under ice-cooling witH stirring, and the stirring was continued at the same temperature for an hour. After concentration of the reaction mixture, the residue was extracted with ethyl acetate, followed by adding 10% hydrochloric acid. The separated aqueous solution was neutralized with an aqueous solution of sodium bicarbonate and then extracted with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to dryness to give an amorphous product (3.0 g), which was chromatographed on silica gel (50 g) using a mixture of chloroform and methanol (50:1 by volume) as an eluent. The eluates containing the desired compound were collected and evaporated to give crystals, which were recrystallized from a mixture of chloroform and diethyl ether to obtain yellow crystals (0.8 g) of 4-(4-benzhydrylpiperazin-l-ylmethyl)-5-chloro-2-ethoxalylaminothiazole, mp I54-156°C.
-
- IR cm-1 (Nujol) : 3070, 1710, 1595, 1240
- NMR δppm (DMSO-d6) : 1.31 (3H, t), 2.29 (4H, m), 2.61 (4H, m), 3.65 (2H, s), 4.20 (2H, q), 4.18 (lH, s), 7.35-7.60 (10H, m)
- Elemental Analysis : C25H27ClN4O3S
- To a solution of 2-amino-4-[2-(4-benzhydryl- piperazin-1-yl)ethylthiomethyl]thiazole (1.5 g) in tetrahydrofuran (50 ml) and pyridine (15 ml) was added dropwise acetyl chloride (l.l ml) under ice-cooling with stirring, and the stirring was continued at the same temperature for an hour. After concentration of the reaction mixture, the residue was extracted with ethyl acetate. The extract was washed with an aqueous solution of sodium bicarbonate and water, dried over anhydrous magnesium sulfate, and then evaporated to give an amorphous product (1.7 g), which was chromatographed on silica gel (20 g) using a mixture of chloroform and methanol (20:1 by volume) as an eluent. The eluates containing the desired compound were collected and evaporated to give a residue, which was transformed into fumarate in a conventional manner. Recrystallization from ethanol gave pale yellow crystals (1.5 g) of 2-acetamido-4-[2-(4-benzhydrylpiperazin-l-yl)ethylthiomethyl]thiazole monofumarate, mp 225-227°C.
-
- IR cm 1 (Nujol) : 3300, 2400, 1695, 1685, 1540, 760
- NMR 6ppm (DMSO-d6) : 2.10 (3H, s), 2.3-2.5 (8H, broad), 3.75 (2H, s), 4.30 (lH, s), 6.00 (5H, broad), 6.75 (2H, s), 7.0 (lH, s), 7.2-7.5 (10H, m)
- Elemental Analysis : C25H30N4OS2·C4H4O4
- A mixture of 2-acetamido-5-[2-(4-benzhydryl- piperazin-l-yl)ethyl]-4-methylthiazole (2.1 g), conc. hydrochloric acid (12 ml) and methanol (50 ml) was refluxed under heating for 5 hours. After concentration of the reaction mixture, the residue was neutralized with an aqueous solution of sodium bicarbonate, followed by extraction with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and then evaporated to give an amorphous product (2.0 g). To the solution of this amorphous product and triethylamine (1.34 ml) in chloroform (20 ml) was added dropwise mesyl chloride (0.74 ml) under ice-cooling with stirring, and the stirring was continued at the same temperature for 1.8 hours. The reaction mixture was washed with water, dried over anhydrous magnesium sulfate and then evaporated to give an oil (2.5 g), which was chromatographed on silica gel (50 g) using a mixture of chloroform and methanol (50:1 by volume) as an eluent. The eluates containing the desired compound were collected and evaporated to give an oil (2.0 g), which was transformed into its hydrochloride in a conventional manner, followed by recrystallization from methanol to obtain white crystals (1.4 g) of 5-[2-(4-benzhydrylpiperazin-1-yl)ethyl]-2-methanesulfonamido-4-methylthiazole trihydrochloride, mp 195-205°C.
-
- IR cm-1 (Nujol) : 3450, 1635, 1540, 1275, 1125, 760
- NMR 6ppm (DMSO-d6) : 2.16 (3H, s), 2.92 (3H, s), 3.2-3.8 (12H, broad), 5.63 (lH, broad), 7.3-7.9 (10H, m)
- S-(2-Aminothiazol-4-ylmethyl)isothiourea dihydrochloride (2.6 g) and 4-benzhydryl-1-(2-chloroethyl)-piperazine (3.87 g) were suspended in ethanol (50 ml) in a stream of nitrogen, and thereto was added at a time water (30 ml) containing sodium hydroxide (2.8 g) at ambient temperature with stirring, and the stirring was continued at 50°C for half an hour. The precipitated crystals were collected by filtration, washed with ethanol and then recrystallized from methanol to give pale yellow crystals (3.0g) of 2-amino-4-[2-(4- benzhydrylpiperazin-1-yl)ethylthiomethyl]thiazole, mp 159-161°C.
-
- IR cm-1 (Nujol) : 3300, 3100, 1670, 1530, 760, 710
- NMR 6ppm (DMSO-d6) : 2.60 (12H, m), 3.50 (2H, s), 4.21 (lH, s), 6.25 (lH, s), 6.90 (2H, s), 7.3-7.6 (10H, m)
- Elemental Analysis : C23H28N4S2
- To a suspension of 4-(4-benzhydrylpiperazin-l-ylmethyl)-2-methanesulfonamidothiazole (1.37 g) in water (31 ml) and methanol (80 ml) was added 0.1 N aqueous solution of sodium hydroxide (31 ml) with stirring, followed by warming the reaction mixture for dissolving it. After concentration of the reaction mixture, the residual crystals were recrystallized from a mixture of methanol and water to obtain pale yellow crystals (1.1 g) of sodium salt of 4-(4- benzhydrylpiperazin-1-ylmethyl)-2-methanesulfonamido- thiazole, mp 165-175°C (dec.).
-
- IR cm-1 (Nujol) : 1590, 1440, 1260, 1120, 705
- NMR δppm (DMSO-d6) : 2.4-2.6 (8H, m), 2.71 (3H, s), 3.31 (2H, s), 4.33 (lH, s), 6.34 (1H, s), 7.3-7.6 (lOH, m)
- Elemental Analysis : C22H25N4O2S2Na'1/2H2O
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT80304740T ATE5138T1 (en) | 1980-01-03 | 1980-12-29 | THIAZOLE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8000162 | 1980-01-03 | ||
GB8000162 | 1980-01-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0032058A1 true EP0032058A1 (en) | 1981-07-15 |
EP0032058B1 EP0032058B1 (en) | 1983-10-26 |
Family
ID=10510425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP80304740A Expired EP0032058B1 (en) | 1980-01-03 | 1980-12-29 | Thiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same |
Country Status (6)
Country | Link |
---|---|
US (1) | US4411900A (en) |
EP (1) | EP0032058B1 (en) |
JP (1) | JPS56103168A (en) |
AT (1) | ATE5138T1 (en) |
CA (1) | CA1154764A (en) |
DE (1) | DE3065435D1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3332148A1 (en) * | 1982-11-19 | 1984-05-24 | Kotobuki Seiyaku Co Ltd | THIAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THEM |
WO1989011476A1 (en) * | 1988-05-27 | 1989-11-30 | Warner-Lambert Company | Substituted 2-aminothiazoles as dopaminergic agents |
EP0207901B1 (en) * | 1985-06-20 | 1990-11-28 | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY | Antianaphylactic and antibronchospastic n-benzhydryldiazacycloalkylalkananilides |
EP0409048A2 (en) * | 1989-07-18 | 1991-01-23 | BASF Aktiengesellschaft | Aminoalkyl substituted 2-aminothiazoles and medicines containing them |
EP0657442A3 (en) * | 1993-12-02 | 1995-07-19 | Asahi Chemical Co | |
WO2001079188A1 (en) * | 2000-04-17 | 2001-10-25 | Cipla Limited | Antihistaminic compounds |
WO2007137417A1 (en) * | 2006-05-26 | 2007-12-06 | Neuromed Pharmaceuticals Ltd. | Heterocyclic compounds as calcium channel blockers |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59155375A (en) * | 1983-02-22 | 1984-09-04 | Kotobuki Seiyaku Kk | Thiazole derivative and its preparation |
JP2690742B2 (en) * | 1987-03-30 | 1997-12-17 | 第一製薬株式会社 | Heterocyclic amine derivative |
US5130443A (en) * | 1991-04-29 | 1992-07-14 | Xerox Corporation | Process for the preparation of anilides |
US20100189768A1 (en) * | 2007-07-11 | 2010-07-29 | Fertin Pharma A/S | Compressed chewing gum tablet comprising taste-masking agent |
WO2009006898A1 (en) * | 2007-07-11 | 2009-01-15 | Fertin Pharma A/S | Stable medicated chewing gum comprising cyclodextrin inclusion complex |
CN102993117A (en) * | 2012-11-28 | 2013-03-27 | 张家港市大伟助剂有限公司 | Preparation method of 2-amino-5-(4-amino phenyl)-thiazole |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3519637A (en) * | 1966-12-06 | 1970-07-07 | Hoffmann La Roche | 1-(4-thiazolylmethyl)nitroimidazole derivatives |
GB1382887A (en) * | 1971-06-14 | 1975-02-05 | Roussel Uclaf | Thiazole-5-carboxylic acid esters |
GB1405365A (en) * | 1972-03-22 | 1975-09-10 | Roussel Uclaf | N,-substituted-thiazole-5-carboxamide derivatives methods for their preparation and compositions containing them |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL72956C (en) * | 1947-11-12 | |||
US2909523A (en) * | 1957-10-11 | 1959-10-20 | American Cyanamid Co | Substituted piperazines and method of preparing the same |
DE1595923A1 (en) * | 1965-02-20 | 1969-11-27 | Merck Ag E | 1-Aralkyl-4- (thiazolyl-2) -piperazines and processes for their preparation |
US3362956A (en) * | 1965-08-19 | 1968-01-09 | Sterling Drug Inc | 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines |
GB1184714A (en) * | 1965-12-16 | 1970-03-18 | Science Union & Cie | Di- and Tri-Phenylpropyl Piperazine Derivatives |
US3491098A (en) * | 1967-05-29 | 1970-01-20 | Sterling Drug Inc | 1-((imidazolyl)-lower-alkyl)-4-substituted-piperazines |
GB1239553A (en) * | 1967-08-16 | 1971-07-21 | ||
GB1240648A (en) * | 1967-08-16 | 1971-07-28 | Wyeth John & Brother Ltd | N-substituted isatins |
BE747274R (en) * | 1969-03-20 | 1970-08-17 | Fujisawa Pharmaceutical Co | METHODS FOR THE PREPARATION OF N-SUBSTITUTE AND N, N-DISUBSTITUTED AMINOCARBONYLALKYL COMPOUNDS AND NEW PRODUCTS THUS OBTAINED |
DE2138865A1 (en) * | 1970-08-15 | 1973-02-22 | Sumitomo Chemical Co | 3-INDOLYLPIPERAZINE, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS |
US3751416A (en) * | 1971-05-27 | 1973-08-07 | American Cyanamid Co | 3-(2-(4-phenyl-1-piperazinyl)-ethyl)indolines |
US3772919A (en) * | 1972-02-09 | 1973-11-20 | Hunter Eng Co | Balancing apparatus for rotating bodies and method of producing frequency stable phase delay |
JPS5070389A (en) * | 1973-10-30 | 1975-06-11 |
-
1980
- 1980-12-11 US US06/215,372 patent/US4411900A/en not_active Expired - Lifetime
- 1980-12-23 CA CA000367494A patent/CA1154764A/en not_active Expired
- 1980-12-29 EP EP80304740A patent/EP0032058B1/en not_active Expired
- 1980-12-29 AT AT80304740T patent/ATE5138T1/en not_active IP Right Cessation
- 1980-12-29 JP JP18934180A patent/JPS56103168A/en active Granted
- 1980-12-29 DE DE8080304740T patent/DE3065435D1/en not_active Expired
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3519637A (en) * | 1966-12-06 | 1970-07-07 | Hoffmann La Roche | 1-(4-thiazolylmethyl)nitroimidazole derivatives |
GB1382887A (en) * | 1971-06-14 | 1975-02-05 | Roussel Uclaf | Thiazole-5-carboxylic acid esters |
GB1405365A (en) * | 1972-03-22 | 1975-09-10 | Roussel Uclaf | N,-substituted-thiazole-5-carboxamide derivatives methods for their preparation and compositions containing them |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3332148A1 (en) * | 1982-11-19 | 1984-05-24 | Kotobuki Seiyaku Co Ltd | THIAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THEM |
EP0207901B1 (en) * | 1985-06-20 | 1990-11-28 | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY | Antianaphylactic and antibronchospastic n-benzhydryldiazacycloalkylalkananilides |
WO1989011476A1 (en) * | 1988-05-27 | 1989-11-30 | Warner-Lambert Company | Substituted 2-aminothiazoles as dopaminergic agents |
EP0345533A1 (en) * | 1988-05-27 | 1989-12-13 | Warner-Lambert Company | Substituted 2-aminothiazoles as dopaminergic agents |
US4935424A (en) * | 1988-05-27 | 1990-06-19 | Warner-Lambert Company | 4 or 5-(substituted piperazinylalkyl)-2-aminothiazoles as antipsychotic agents |
EP0409048A2 (en) * | 1989-07-18 | 1991-01-23 | BASF Aktiengesellschaft | Aminoalkyl substituted 2-aminothiazoles and medicines containing them |
EP0409048A3 (en) * | 1989-07-18 | 1991-05-15 | Basf Aktiengesellschaft | Aminoalkyl substituted 2-aminothiazoles and medicines containing them |
EP0657442A3 (en) * | 1993-12-02 | 1995-07-19 | Asahi Chemical Co | |
WO2001079188A1 (en) * | 2000-04-17 | 2001-10-25 | Cipla Limited | Antihistaminic compounds |
WO2007137417A1 (en) * | 2006-05-26 | 2007-12-06 | Neuromed Pharmaceuticals Ltd. | Heterocyclic compounds as calcium channel blockers |
Also Published As
Publication number | Publication date |
---|---|
ATE5138T1 (en) | 1983-11-15 |
US4411900A (en) | 1983-10-25 |
DE3065435D1 (en) | 1983-12-01 |
EP0032058B1 (en) | 1983-10-26 |
JPH0114229B2 (en) | 1989-03-10 |
JPS56103168A (en) | 1981-08-18 |
CA1154764A (en) | 1983-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7612200B2 (en) | Inhibitors of protein kinases | |
US6348477B1 (en) | Anti-herpesvirus compounds and methods for identifying, making and using same | |
ES2315566T3 (en) | TIAZOLIDIN-4-ONAS TO INHIBIT HYAK3 PROTEINS. | |
ES2324922T3 (en) | DERIVATIVES OF TIAZOL THAT HAVE INHIBITING ACTIVITY OF VAP-1. | |
US4411900A (en) | Benzhydrylpiperozinyl thiazole derivatives and pharmaceutical composition comprising the same | |
HU211557A9 (en) | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same | |
ES2336425T3 (en) | DERIVATIVES OF USEFUL TIAZOLS AS ANTI-INFLAMMATORY AGENTS. | |
US4742057A (en) | Antiallergic thiazole compounds | |
US4591590A (en) | Benzhydrylpiperazine derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | |
EP0308917A2 (en) | Imidazopyridine compound, a process for preparation thereof and pharmaceutical compositions comprising them | |
JP2008524139A (en) | Meta-substituted thiazolinones, their production and use as pharmaceuticals | |
EP0059597B1 (en) | Guanidino-substituted heterocyclic derivatives having histamine h-2 antagonist activity | |
US5371097A (en) | Thiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | |
EP0316820B1 (en) | Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | |
NZ188770A (en) | Thiazolinylguanidine derivatives and pharmaceutical compositions | |
US5369107A (en) | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same | |
EP0010398B1 (en) | Isatin derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | |
JP2531329B2 (en) | New compound | |
EP0060093B1 (en) | Amide derivatives | |
EP1123283A1 (en) | Thiazole-derivatives | |
ES2238463T3 (en) | HYDROXIIMINO-HETEROCICLIC FLUORENS AND USE TO INHIBIT PROTEIN-KINASES. | |
US5364871A (en) | New thiazole derivatives, and pharmaceutical composition comprising the same | |
EP0575614A1 (en) | Thiazole derivatives | |
CS241503B2 (en) | Method of guanidine derivatives production | |
MXPA01004000A (en) | Thiazole-derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
17P | Request for examination filed |
Effective date: 19811215 |
|
ITF | It: translation for a ep patent filed |
Owner name: MODIANO & ASSOCIATI S.R.L. |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19831026 Year of fee payment: 4 |
|
REF | Corresponds to: |
Ref document number: 5138 Country of ref document: AT Date of ref document: 19831115 Kind code of ref document: T |
|
ET | Fr: translation filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19831130 Year of fee payment: 4 |
|
REF | Corresponds to: |
Ref document number: 3065435 Country of ref document: DE Date of ref document: 19831201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19831231 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19841207 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19841215 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19841217 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19841231 Year of fee payment: 5 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 19851213 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19851231 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Effective date: 19861229 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19861230 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19861231 Ref country code: CH Effective date: 19861231 Ref country code: BE Effective date: 19861231 |
|
BERE | Be: lapsed |
Owner name: FUJISAWA PHARMACEUTICAL CO. LTD Effective date: 19861231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19870701 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19870831 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19870901 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19881118 |
|
EUG | Se: european patent has lapsed |
Ref document number: 80304740.6 Effective date: 19870902 |